<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cell. Infect. Microbiol.</journal-id>
<journal-title>Frontiers in Cellular and Infection Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cell. Infect. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">2235-2988</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fcimb.2022.887647</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cellular and Infection Microbiology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Proteomic and Functional Analysis of the Effects of Quinoxaline Derivatives on <italic>Entamoeba histolytica</italic>
</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Avila-Bonilla</surname>
<given-names>Rodolfo Gamaliel</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1482419"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>L&#xf3;pez-Sandoval</surname>
<given-names>&#xc1;ngel</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1856758"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Soto-S&#xe1;nchez</surname>
<given-names>Jacqueline</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marchat</surname>
<given-names>Laurence A.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/539729"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rivera</surname>
<given-names>Gildardo</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/60162"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Medina-Contreras</surname>
<given-names>Oscar</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/604571"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ram&#xed;rez-Moreno</surname>
<given-names>Esther</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1405430"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Instituto Polit&#xe9;cnico Nacional, Escuela Nacional de Medicina y Homeopat&#xed;a, Laboratorio de Biomedicina Molecular 2</institution>, <addr-line>M&#xe9;xico City</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Instituto Polit&#xe9;cnico Nacional, Centro de Biotecnolog&#xed;a Gen&#xf3;mica, Laboratorio de Biotecnolog&#xed;a Farmac&#xe9;utica</institution>, <addr-line>Reynosa</addr-line>, <country>Mexico</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Hospital Infantil de M&#xe9;xico Federico G&#xf3;mez, Unidad de Investigaci&#xf3;n Epidemiol&#xf3;gica en Endocrinolog&#xed;a y Nutrici&#xf3;n (UIEEN)</institution>, <addr-line>M&#xe9;xico City</addr-line>, <country>Mexico</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Martin Craig Taylor, University of London, United Kingdom</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Danilo Ciccone Miguel, State University of Campinas, Brazil; Igor Cestari, McGill University, Canada</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Esther Ram&#xed;rez-Moreno, <email xlink:href="mailto:maramirezmo@ipn.mx">maramirezmo@ipn.mx</email>; <email xlink:href="mailto:estherramirezmoreno@yahoo.com">estherramirezmoreno@yahoo.com</email>
</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Parasite and Host, a section of the journal Frontiers in Cellular and Infection Microbiology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>27</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>12</volume>
<elocation-id>887647</elocation-id>
<history>
<date date-type="received">
<day>01</day>
<month>03</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>05</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Avila-Bonilla, L&#xf3;pez-Sandoval, Soto-S&#xe1;nchez, Marchat, Rivera, Medina-Contreras and Ram&#xed;rez-Moreno</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Avila-Bonilla, L&#xf3;pez-Sandoval, Soto-S&#xe1;nchez, Marchat, Rivera, Medina-Contreras and Ram&#xed;rez-Moreno</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Quinoxalines are heterocyclic compounds that contain a benzene ring and a pyrazine ring. The oxidation of both nitrogen of the pyrazine ring results in quinoxaline derivatives (QdNO), which exhibit a variety of biological properties, including antiparasitic activity. However, its activity against <italic>Entamoeba histolytica</italic>, the protozoan that causes human amebiasis, is poorly understood. Recently, our group reported that various QdNOs produce morphological changes in <italic>E. histolytica</italic> trophozoites, increase reactive oxygen species, and inhibit thioredoxin reductase activity. Notably, T-001 and T-017 derivatives were among the QdNOs with the best activity. In order to contribute to the characterization of the antiamebic effect of QdNOs, in this work we analyzed the proteomic profile of <italic>E. histolytica</italic> trophozoites treated with the QdNOs T-001 and T-017, and the results were correlated with functional assays. A total number of 163 deregulated proteins were found in trophozoites treated with T-001, and 131 in those treated with T-017. A set of 21 overexpressed and 24 under-expressed proteins was identified, which were mainly related to cytoskeleton and intracellular traffic, nucleic acid transcription, translation and binding, and redox homeostasis. Furthermore, T-001 and T-017 modified the virulence of trophozoites, since they altered their erythrophagocytosis, migration, adhesion and cytolytic capacity. Our results show that in addition to alter reactive oxygen species, and thioredoxin reductase activity, T-001 and T-017 affect essential functions related to the actin cytoskeleton, which eventually affects <italic>E. histolytica</italic> virulence and survival.</p>
</abstract>
<kwd-group>
<kwd>
<italic>E. histolytica</italic>
</kwd>
<kwd>quinoxaline derivatives</kwd>
<kwd>proteomics</kwd>
<kwd>functional analysis</kwd>
<kwd>Antiamoebic activity</kwd>
</kwd-group>
<contract-num rid="cn001">20200335</contract-num>
<contract-num rid="cn002">285467</contract-num>
<contract-sponsor id="cn001">Secretar&#xed;a de Investigaci&#xf3;n y Posgrado, Instituto Polit&#xe9;cnico Nacional<named-content content-type="fundref-id">10.13039/501100007161</named-content>
</contract-sponsor>
<contract-sponsor id="cn002">Consejo Nacional de Ciencia y Tecnolog&#xed;a<named-content content-type="fundref-id">10.13039/501100003141</named-content>
</contract-sponsor>
<contract-sponsor id="cn003">Comisi&#xf3;n de Operaci&#xf3;n y Fomento de Actividades Acad&#xe9;micas, Instituto Polit&#xe9;cnico Nacional<named-content content-type="fundref-id">10.13039/501100007177</named-content>
</contract-sponsor>
<contract-sponsor id="cn004">Sistema Nacional de Investigadores<named-content content-type="fundref-id">10.13039/501100013395</named-content>
</contract-sponsor>
<counts>
<fig-count count="4"/>
<table-count count="4"/>
<equation-count count="0"/>
<ref-count count="51"/>
<page-count count="13"/>
<word-count count="7406"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Quinoxalines are heterocyclic compounds made up of a benzene and pyrazine ring. The quinoxaline ring is described as a bioisostere of quinoline, naphthalene, benzothiophene and other aromatic cycles such as pyridine and pyrazine, some of which are the basis of known antimalarial and antitubercular agents for clinical use (<xref ref-type="bibr" rid="B48">Vicente et&#xa0;al., 2007</xref>). Quinoxalines 1,4-di-N-oxides are a class of quinoxaline derivatives that possess two N-O bonds at the N1 and N4 positions, respectively (<xref ref-type="bibr" rid="B29">Mu et&#xa0;al., 2014</xref>). The quinoxaline derivatives 1,4-di-N -oxides (QdNOs) are obtained by small modifications in the structure of the ring, especially in the positions R2, R3, R6 and R7, which have been related to differences in the biological activity and therefore selectivity (<xref ref-type="bibr" rid="B26">Leeson et&#xa0;al., 2004</xref>; <xref ref-type="bibr" rid="B38">Santiva&#xf1;ez-Veliz et&#xa0;al., 2013</xref>). N-oxide groups are the main functional groups of quinoxaline derivatives (<xref ref-type="bibr" rid="B17">Gonz&#xe1;lez et&#xa0;al., 2007</xref>). The presence of N-oxide groups in QdNOs allows their varied biological properties, including their effects against protozoa that affect human health, such as <italic>Plasmodium falciparum</italic> (<xref ref-type="bibr" rid="B5">Bonilla-Ramirez et&#xa0;al., 2018</xref>), <italic>Trypanosoma cruzi</italic> and <italic>Leishmania mexicana</italic> (<xref ref-type="bibr" rid="B9">Chac&#xf3;n-Vargas et&#xa0;al., 2017</xref>), and <italic>Trichomonas vaginalis</italic> (<xref ref-type="bibr" rid="B7">Carta et&#xa0;al., 2004</xref>). Although some mechanisms have been described in several protozoa, very little is known about the activity of QdNOs against <italic>Entamoeba histolytica</italic>, the protozoan that causes human amoebiasis. This disease is one of the main causes of mortality and morbidity in developing countries, being the third parasitic disease with the highest mortality after malaria and schistosomiasis (<xref ref-type="bibr" rid="B50">WHO, 1998</xref>). Although the drug of choice for the treatment of intestinal and extraintestinal amoebiasis is metronidazole, its use produces adverse effects and has been associated with carcinogenesis (<xref ref-type="bibr" rid="B37">Rustia and Shubik, 1972</xref>), mutagenesis and teratogenesis (<xref ref-type="bibr" rid="B23">Kazy et&#xa0;al., 2005</xref>). Additionally, several strains of <italic>E. histolytica</italic> resistant to metronidazole have been obtained in the laboratory (<xref ref-type="bibr" rid="B46">Upcroft and Upcroft, 1993</xref>; <xref ref-type="bibr" rid="B47">Upcroft and Upcroft, 2001</xref>), which evidences the necessity of developing new drugs to control this parasitosis.</p>
<p>
<xref ref-type="bibr" rid="B12">Duque-Monta&#xf1;o et&#xa0;al. (2013)</xref> evaluated the effect of 25 new compounds derived from QdNOs which had various substituents at the R2, R3 and R7 positions, on cultures of <italic>E. histolytica</italic> trophozoites (HM1: IMSS strain). Of these 25 ethyl and methyl quinoxalines 7-carboxylate 1,4-di-N-oxide (7-carboxylate QdNOs), 10 showed a better antiamebic activity than metronidazole, the reference drug. Moreover, by comparing the antiamebic activity and cytotoxic activity in Vero cells, the compounds that presented the best selectivity index (SI) were T-017 (SI&gt; 51.81), T-014 (SI&gt; 53.19), T-001 (IS&gt; 68.02) and T-016 (IS&gt; 70.92), suggesting that these molecules could be valuable candidates as antiamebic drugs (<xref ref-type="bibr" rid="B12">Duque-Monta&#xf1;o et&#xa0;al., 2013</xref>). Recently, <xref ref-type="bibr" rid="B42">Soto-S&#xe1;nchez et&#xa0;al., 2020</xref>, showed that these four 7-carboxylate QdNOs produce morphological changes in <italic>E. histolytica</italic> trophozoites, including chromatin remodelling, cellular granularity and redistribution of vacuoles, as well as an increase in reactive oxygen species (ROS). Additionally, molecular docking analysis indicated that the compounds can interact with amino acid residues of the NADH-binding domain and the redox active site of <italic>E. histolytica</italic> thioredoxin reductase (EhTrxR); complementary enzyme assays showed that the compounds inhibit its disulfide reductase and diaphorase activity, acting as electron acceptor substrate for this enzyme.</p>
<p>In this work, we selected T-001 and T-017 that have the best antiamebic properties and evaluate their effect on protein expression in <italic>E. histolytica.</italic> We also performed functional assays to assess the impact of deregulated proteins on parasite virulence properties that depends on cytosqueleton dynamics, which complements our knowledge about the mechanisms of action of QdNOs on this parasite.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="s2_1">
<title>Synthetic Compounds</title>
<p>Quinoxaline derivatives T-001 (Methyl 2-acetyl-3-methyl-quinoxaline-7-carboxylate 1,4-di-N-oxide) and T-017 (Ethyl 2-benzoyl-3-methylquinoxaline-7-carboxylate 1,4-di-N-oxide) were synthesized as described (<xref ref-type="bibr" rid="B16">G&#xf3;mez-Caro et&#xa0;al., 2011</xref>). Stock solutions were prepared in DMSO (the concentration used in the experiments did not exceed 0.01%) and each compound was prepared at a final concentration of 1 mg/mL. Metronidazole (Sigma-Aldrich) was used as a reference drug.</p>
</sec>
<sec id="s2_2">
<title>
<italic>E. histolytica</italic> Culture and Treatments</title>
<p>
<italic>E. histolytica</italic> trophozoites (HM1: IMSS strain) were axenically cultured in 75 cm<sup>2</sup> culture flasks at 37&#xb0;C in TYIS-33 medium supplemented with 16.8% (v/v) heat-inactivated adult bovine serum (<xref ref-type="bibr" rid="B11">Diamond et&#xa0;al., 1978</xref>), 3.2% (v/v) Diamond Vitamin-Tween 80 solution (Sigma-Aldrich), 100 U/mL penicillin, and 100 &#x3bc;g/mL streptomycin. Trophozoites were treated for 48&#xa0;h at 37&#xb0;C with the IC<sub>50</sub> of T-001 (1.41 &#xb5;M) or T-017 (1.93 &#xb5;M), previously reported by <xref ref-type="bibr" rid="B12">Duque-Monta&#xf1;o et&#xa0;al. (2013)</xref>. Parasites without treatment were included as controls. This experiment was carried out in triplicate.</p>
</sec>
<sec id="s2_3">
<title>Protein Extraction and Cleaning</title>
<p>Trophozoites were centrifuged and washed with PBS pH 6.8 at 4&#xb0;C and resuspended in 1&#xa0;ml buffer lysis, (50 mM Tris pH 7.4, 0.25% SDS, protease inhibitors: 0.04 mM E-64, 100 &#xb5;M Leupeptin, 7 mM PMSF, 8.75 mM iodoacetamide and protease inhibitor cocktail [Complete, Roche]). After homogenization, trophozoites were lysed by freeze-thaw cycles; the solution was centrifuged at 16,000 g for 5&#xa0;min at 4&#xb0;C and the supernatant was distributed in aliquots in Eppendorf tubes and stored at -80&#xb0;C, until use.</p>
<p>Protein cleaning and purification were carried out by acetone precipitation, the proteins were obtained by centrifugation at 21,000 g for 5&#xa0;min at 4&#xb0;C, the pellet was allowed to air dry and resuspended in rehydration buffer (7 M urea, 2 M thiourea, 2% CHAPS, 40 mM DTT, 0.5% ampholytes 4-7, and traces of bromophenol blue).</p>
</sec>
<sec id="s2_4">
<title>2D-DIGE (Two-Dimensional-Differential-in-Gel-Electrophoresis) Analysis</title>
<p>Protein extract (500 &#xb5;g) were applied to acrylamide gel strips with an immobilized linear gradient of pH 4.0-7.0 (ReadyStrip &#x2122; IPG strips pH 4.0-7.0, BioRad). Isoelectric focusing was performed with the Protean IEF i12 &#x2122; cell system (BioRad), following the recommendations of the commercial company, under the following conditions: step 1: 250&#xa0;V for 20&#xa0;min, step 2: 8000&#xa0;V for 1h, step 3: 8000&#xa0;V for 26&#xa0;h, step 4: 1500&#xa0;V sustained. For the second dimension, the IPG strips were placed directly on the 12% polyacrylamide gel, along with 7 &#xb5;L of pre-stained molecular weight marker (Bio-Rad). Electrophoresis was carried out at 80&#xa0;V for 15&#xa0;min, and at 200&#xa0;V until the end of the run. The gel was immersed for 1&#xa0;h in fixing solution (50% methanol, 10% acetic acid), washed three times with Milli-Q water for 10&#xa0;min and stained with Sypro<sup>&#xae;</sup> Ruby Protein Gel Stain (Invitrogen &#x2122;, Molecular Probes) according to the supplier recommendations. Finally, the stained gel was visualized with UV light through the ChemiDocs XRS system (Bio-Rad Laboratories), images were acquired using the Image lab 5.2.1 software (Bio-Rad Laboratories) and spots were detected with the PDQuest 8.0.1 software (Bio-Rad Laboratories). The protein profiles of the biological triplicates for each condition were normalized using a synthetic image called MatchSet master. Subsequently, the intensity of the spots was normalized according to the total intensity of the valid spots, in order to minimize possible errors due to differences in the amount of protein and intensity of the staining. The Student&#xb4;s t test was used to determine any significant differences in spot intensity (p&lt;0.05).</p>
<p>The protein profiles corresponding to the treatment with T-001 and T-017 were compared with that of trophozoites without treatment. Only those spots that showed a Fold change&gt; 2-fold between control and treatments were considered as differentially expressed proteins and selected for subsequent analysis by mass spectrometry (MS), according to Student&#xb4;s t test (p&lt;0.05).</p>
</sec>
<sec id="s2_5">
<title>Mass Spectrometry</title>
<p>A total of 45 spots were selected and excised with the EXQuest spot cutter (Bio-Rad Laboratories). They were bleached using acetonitrile (C<sub>2</sub>H<sub>3</sub>N) and 50 mM ammonium bicarbonate (NH<sub>4</sub>CO<sub>3</sub>) in a 1:1 ratio for 15&#xa0;min, and then washed with 50 &#xb5;L acetonitrile for 5&#xa0;min. All the liquid was removed, and samples were dried in a vacuum centrifuge. Proteins were reduced with 10 mM DTT and 50 mM ammonium bicarbonate for 45&#xa0;min at 56&#xb0;C and alkylated with 55 mM iodoacetamide for 30&#xa0;min at room temperature. Later, they were washed with sodium bicarbonate and acetronitrile, and digested with 0.1 &#xb5;g/&#xb5;L trypsin in 50 mM ammonium bicarbonate, overnight at 37&#xb0;C. The peptides were extracted with 0.1% trifluoroacetic acid and 25 &#xb5;L of acetronitrile for 30&#xa0;min, the solvent was removed by lyophilization and peptides were submitted to a MALDI-TOF/TOF analyzer (Ultraflex III, Bruker, Germany). Mass spectra were acquired in positive ion mode and automatically submitted to Mascot software v.2.1 (<uri xlink:href="http://www.matrixscience.com">http://www.matrixscience.com</uri>) for protein identification against the NCBI database for non-redundant proteins (<uri xlink:href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</uri>). As defined by Mascot probability analysis, only significant scores greater than &#x201c;identity&#x201d; (95% level of confidence) were considered to assign protein identity. All positive protein identification scores were significant (p &lt; 0.05).</p>
<p>The identity of the proteins was corroborated in the amoeba (<uri xlink:href="https://amoebadb.org/amoeba/">https://amoebadb.org/amoeba/</uri>) and Uniprot (<uri xlink:href="https://www.uniprot.org">https://www.uniprot.org</uri>) databases. Subsequently, they were categorized and classified according with their function, using the DAVID Bioinformatics Resources 6.8 (<uri xlink:href="https://david.ncifcrf.gov/">https://david.ncifcrf.gov/</uri>) and the PANTHER classification system (Protein Annotation Through Evolutionary Relationship) (<uri xlink:href="http://www.pantherdb.org/">http://www.pantherdb.org/</uri>). The proteins with unknow function were searched in the Argot 2 program (<uri xlink:href="http://www.medcomp.medicina.unipd.it/Argot2/index.php">http://www.medcomp.medicina.unipd.it/Argot2/index.php</uri>). Finally, information related to the involvement of these proteins in various biological processes in <italic>E. histolytica</italic> was documented.</p>
<p>The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium <italic>via</italic> the PRIDE (<xref ref-type="bibr" rid="B33">Perez-Riverol et&#xa0;al., 2022</xref>) partner repository with the dataset identifier PXD032322.</p>
</sec>
<sec id="s2_6">
<title>Real-Time qRT-PCR</title>
<p>Total RNA was obtained from trophozoites previously treated with the respective quinoxaline derivatives T-001 and T-017, using TRIzol reagent (Thermo Fisher Scientific). RNA from trophozoites growing in standard conditions was used as control. Following DNase 1 treatment, cDNA synthesis was carried out using 5 &#xb5;g of RNA and the SuperScript III First-Strand kit (Invitrogen). Specific primers for Peroxiredoxin putative (Forward, 5&#x2032;-agcatggtgtgaagcagataa-3&#x2032;; Reverse, 5&#x2032;-cctgcttcgacatttaacattcc-3&#x2032;), Actin 2 putative (Forward, 5&#x2032;-atgggagacgaagaagttcaag-3&#x2032;; Reverse, 5&#x2032;-ttgacccataccagccataac-3&#x2032;), Tyrosine kinase (Forward, 5&#x2032;-cagagctgatggtcctccaa-3&#x2032;; Reverse, 5&#x2032;-tgaccaaatgacccagctcc-3&#x2032;), Thioredoxin putative (Forward, 5&#x2032;-ttgtgaatggtgtaaggaaatgag-3&#x2032;; Reverse, 5&#x2032;-gcactggctattaaagaatccatga-3&#x2032;), Adapter protein (Forward, 5&#x2032;-agcctcvtcttgattttgctcca-3&#x2032;; Reverse, 5&#x2032;-acacattgagaagccaaactagg-3&#x2032;) and Cysteinyl-tRNA synthetase (Forward, 5&#x2032;-caaaagtcggtgtacgtgttga-3&#x2032;; Reverse, 5&#x2032;-ttggatctgaagcccaactct-3&#x2032;) were used in qPCR assays. Primers to amplify the RNA polymerase II gene (Forward, 5&#x2032;-gatccaacatatcctaaaacaaca-3&#x2032;; Reverse, 5&#x2032;-tcaattattttctgacccgtcttc-3&#x2032;) were used as internal control (<xref ref-type="bibr" rid="B31">Penuliar et&#xa0;al., 2012</xref>). The reactions were carried out in Fast Optical 48-Well Reaction Plates using 500 ng of cDNA, 5 &#xb5;M of primers and 5 &#xb5;L of Sensi FAST SYBR Hi-ROX master mix (Bioline). To ensure the presence of specific products, the denaturation curve (melt curve) was carried out and the relative expression of the genes was calculated by the &#x394;&#x394;CT method (<xref ref-type="bibr" rid="B27">Livak &amp; Schmittgen, 2001</xref>). Three independent and triplicate experiments were done. Data were analyzed using the Tukey test with the Sigma Stat version 2 software.</p>
</sec>
<sec id="s2_7">
<title>Cell Migration Assay</title>
<p>Trophozoites previously treated for 48&#xa0;h with the IC<sub>50</sub> of T-001 or T-017 (as mentioned above), were incubated in TYI-S-33 medium without serum for 3&#xa0;h at 37&#xb0;C (Serum starvation) (<xref ref-type="bibr" rid="B13">Franco et&#xa0;al., 1997</xref>). They were chilled on ice for 5&#xa0;min, centrifuged at 320 x g for 5&#xa0;min and washed three times in TBS-CaCl<sub>2</sub> buffer (50 mM Tris, 150 mM NaCl and 1 mM CaCl<sub>2</sub>, pH 7.2). Then, 5x10<sup>4</sup> trophozoites were placed in the upper part of a transwell chamber (8 &#xb5;m, Corning), while 600 &#xb5;L of TYI-S-33 medium with serum was placed in the lower compartment. Cells were incubated at 37&#xb0;C for 3&#xa0;h and the number of trophozoites that migrated to the lower compartment was determined by counting in a Neubauer chamber and staining with 0.4% trypan blue (<xref ref-type="bibr" rid="B14">Gilchrist et&#xa0;al., 2008</xref>). The tests were carried out three times in triplicate. Untreated trophozoites and parasites treated with DMSO 0.01% were included as controls. The results were expressed as the mean of migration percentage &#xb1; standard deviation (SD). The comparisons between groups were carried out with the one way ANOVA test.</p>
</sec>
<sec id="s2_8">
<title>Adhesion Assay</title>
<p>Trophozoites previously treated with the selected QdNOs were washed and resuspended in 1 mL of TYI-S-33 medium without serum; later they were seeded on monolayers of SW-480 cells previously cultured in 24-well plates, in a ratio of 1 trophozoite per 4 cells. The plates were incubated at 37&#xb0;C for 15&#xa0;min, after which the unattached trophozoites were removed from the culture medium, centrifuged at 320 x g for 5&#xa0;min and counted using a Neubauer chamber. The tests were carried out in triplicate (<xref ref-type="bibr" rid="B24">Kobiler and Mirelman, 1981</xref>). Untreated trophozoites and parasites treated with DMSO 0.01% were included as controls. The results were expressed as the mean of adhesion percentage &#xb1; standard deviation (SD). The comparisons between groups were carried out with the one way ANOVA test.</p>
</sec>
<sec id="s2_9">
<title>Cytolytic Effect</title>
<p>SW-480 cells were seeded in a 24-well plate (1.8x10<sup>5</sup> cells/well) in supplemented RPMI-1640 medium and incubated 48&#xa0;h at 37&#xb0;C with 5% CO<sub>2</sub>. The cell monolayers were washed three times with PBS pH 6.8 and incubated at 37&#xb0;C for 45&#xa0;min with trophozoites (previously treated with selected QdNOs, untreated or DMSO treated, and resuspended in TYI-S-33 medium without serum) in 1:10 ration (amoeba: SW-480 cells). After incubation, the supernatant was removed, and lactate dehydrogenase activity was determined using the CytoTox 96<sup>&#xae;</sup> Non-Radioactive Cytotoxicity Assay Kit, following the manufacturer instructions. Plates were read at 492 nm using a Multiskan FC reader (Thermo Scientific). SW-480 cells or trophozoites only with TYI-S-33 culture medium were used as negative controls; as lysis control, SW-480 cells lysed for 45&#xa0;min with 9% X-100 triton. All conditions were tested in triplicate. Each experiment was repeated three times. The comparisons between groups were carried out with the one way ANOVA test.</p>
</sec>
<sec id="s2_10">
<title>Erythrophagocytosis Assays</title>
<p>Human erythrocytes (0.5 x 10<sup>8</sup> cells/mL) were mixed with an equal volume of <italic>E. histolytica</italic> trophozoites (0.5x10<sup>6</sup> cells/ml). Both cell suspensions were prepared with serum-free medium. Cell mixture was incubated for 0, 5, 10 or 15&#xa0;min at 37&#xb0;C, subsequently fixed with 4% paraformaldehyde (<xref ref-type="bibr" rid="B45">Trissl et&#xa0;al., 1978</xref>), and washed three times with PBS 6.8 to remove non-phagocytosed erythrocytes. Ingested erythrocytes were contrasted by the Novikoff staining method (<xref ref-type="bibr" rid="B30">Novikoff et&#xa0;al., 1972</xref>) using fresh diaminobenzidine solution (3,3'-diaminobenzidine 2 mg/mL, 0.048% H<sub>2</sub>O<sub>2</sub> and 50 Mm Tris-HCL, pH 9.7). The number of ingested erythrocytes was quantified and documented under an optical microscope. The results were expressed as the mean of ingested erythrocyte ratio &#xb1; standard deviation (SD). The comparisons between groups were carried out with the one way ANOVA test.</p>
</sec>
<sec id="s2_11">
<title>Hemoglobin Quantification</title>
<p>Erythrophagocytosis capacity was evaluated by quantitative determination of hemoglobin within trophozoites. After 10&#xa0;min of interaction of the amoeba trophozoites with human erythrocytes as described above, the trophozoites were recovered by washing three times with 1 mL of cold distilled water; then they were lysed with 1 mL formic acid and the amount of hemoglobin was measured by spectrophotometric analysis at 400 nm, using formic acid as blank (<xref ref-type="bibr" rid="B49">Voigt et&#xa0;al., 1999</xref>). The hemoglobin quantitation was obtained in relation to the untreated parasites. The results were expressed as the mean of hemoglobin &#xb1; standard deviation (SD). The comparisons between groups were carried out with the one way ANOVA test.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<p>In order to observe how treatments with T-001 and T-017 affect protein expression, trophozoite extracts were analyzed by two-dimensional electrophoresis, and proteins were visualized by Sypro Ruby staining. The gels corresponding to treated and untreated trophozoites showed an efficient protein separation (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>). Many of the detected amoebic proteins have an isoelectric point (IP) of 5 to 6 and a molecular weight between 20-100 kDa. A total of 669 spots were visualized in untreated trophozoites, whereas 590 and 657 spots were found in proteins extracts from T-001 and T-017 treated cells, respectively. Analysis with the 2D-PD QUEST program revealed that T-001 modified the expression of 163 proteins, 79 were overexpressed and 84 were under expressed compared to the untreated group. Treatment with T-017 produced 131 differentially expressed spots, 70 overexpressed and 61 under expressed (&gt;2 fold change). A set of 24 spots modulated by T-001 (11 overexpressed and 13 under-expressed) (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>), and 21 spots modulated by T-017 (10 overexpressed and 11 under-expressed) (<xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>) were selected for protein identification by mass spectrometry. The proteins with the highest fold change after T-001 treatment were the truncated hsp 70 family protein that was overexpressed with a fold change of 7.26, while the Fbox/WD domain containing protein and the tyrosine kinase were underexpressed with a fold change of 7.87 and 6.08, respectively. On the other hand, the proteins modulated by T-017 with the highest fold change were the Rab GTPase protein, overexpressed with a fold change of 6.42, while the adenylylcyclase associated protein was underexpressed with a fold change of 6.06. Changes in protein abundance were corroborated by Real-time RT-qPCR assays to evaluate the relative mRNA expression of six proteins that were similarly deregulated by T-001 and T-017 (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>). Interestingly, the overexpression of the putative peroxyredoxin gene, and the under-expression of tyrosine kinase, thioredoxin, adapter protein (AP) and cysteinyl-tRNA synthetase genes agreed with the results of protein expression.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Two dimensional differential in gel electrophoresis of <italic>E. histolytica</italic> trophozoite proteins under the effect of T-001 and T-017. Selected spots for protein identification corresponding to proteins with a differential abundance between control trophozoites <bold>(A, C)</bold> and parasites treated with T-001 <bold>(B)</bold> or T-017 <bold>(D)</bold> are indicated in red squares. Underexpressed proteins are marked on gels of untreated trophozoites <bold>(A, C)</bold> and the overexpressed ones are indicated on gels of trophozoites treated with T-001 and T-017 <bold>(B, D)</bold>. The isoelectric focusing was carried out in a non-linear gradient of pH 4-7.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-12-887647-g001.tif"/>
</fig>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Identification of <italic>E. histolytica</italic> proteins that are modulated by QdNO T-001.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Protein(Spot number)</th>
<th valign="top" align="center">Accession number</th>
<th valign="top" align="center">Fold change</th>
<th valign="top" align="center">Mascot score</th>
<th valign="top" align="center">Sequence coverage %</th>
<th valign="top" align="center">Molecular weight (kDa)/IP</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" colspan="6" align="left">
<bold>Overexpressed</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">Actin 2 protein, putative (1)</td>
<td valign="top" align="left">B1N5D1</td>
<td valign="top" align="center">4.45</td>
<td valign="top" align="center">34</td>
<td valign="top" align="center">65</td>
<td valign="top" align="center">81000/5.51</td>
</tr>
<tr>
<td valign="top" align="left">Guanine nucleotide-binding protein subunit beta 2-like 1, putative (2)</td>
<td valign="top" align="left">C4M6P6</td>
<td valign="top" align="center">2.01</td>
<td valign="top" align="center">34</td>
<td valign="top" align="center">22</td>
<td valign="top" align="center">35077/6.82</td>
</tr>
<tr>
<td valign="top" align="left">Truncated hsp70 family protein (3)</td>
<td valign="top" align="left">C4MBG4</td>
<td valign="top" align="center">7.26</td>
<td valign="top" align="center">38</td>
<td valign="top" align="center">53</td>
<td valign="top" align="center">13018/9.55</td>
</tr>
<tr>
<td valign="top" align="left">Vesicle-fusing ATPase (9)</td>
<td valign="top" align="left">C4LYS4</td>
<td valign="top" align="center">4.06</td>
<td valign="top" align="center">38</td>
<td valign="top" align="center">18</td>
<td valign="top" align="center">82693/6.05</td>
</tr>
<tr>
<td valign="top" align="left">40S ribosomal protein S24, putative(10)</td>
<td valign="top" align="left">C4M549</td>
<td valign="top" align="center">2.23</td>
<td valign="top" align="center">48</td>
<td valign="top" align="center">37</td>
<td valign="top" align="center">16260/10.39</td>
</tr>
<tr>
<td valign="top" align="left">TBC domain containing protein (11)</td>
<td valign="top" align="left">C4M7P5</td>
<td valign="top" align="center">2.44</td>
<td valign="top" align="center">38</td>
<td valign="top" align="center">28</td>
<td valign="top" align="center">36.208/6.19</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (12)</td>
<td valign="top" align="left">C4M893</td>
<td valign="top" align="center">2.97</td>
<td valign="top" align="center">30</td>
<td valign="top" align="center">27</td>
<td valign="top" align="center">21.521/9.57</td>
</tr>
<tr>
<td valign="top" align="left">Protein phosphatase, putative (14)</td>
<td valign="top" align="left">C4LU84</td>
<td valign="top" align="center">3.01</td>
<td valign="top" align="center">25</td>
<td valign="top" align="center">23</td>
<td valign="top" align="center">36607/4.59</td>
</tr>
<tr>
<td valign="top" align="left">Peroxiredoxin, putative (17)</td>
<td valign="top" align="left">B1N5Y9</td>
<td valign="top" align="center">2.07</td>
<td valign="top" align="center">34</td>
<td valign="top" align="center">69</td>
<td valign="top" align="center">14744/7.61</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (18)</td>
<td valign="top" align="left">B1N2E4</td>
<td valign="top" align="center">2.36</td>
<td valign="top" align="center">54</td>
<td valign="top" align="center">29</td>
<td valign="top" align="center">28062/8.22</td>
</tr>
<tr>
<td valign="top" align="left">Calmodulin, putative(19)</td>
<td valign="top" align="left">C4LTA2</td>
<td valign="top" align="center">2.69</td>
<td valign="top" align="center">20</td>
<td valign="top" align="center">96</td>
<td valign="top" align="center">6265/12.03</td>
</tr>
<tr>
<td valign="top" colspan="6" align="left">
<bold>Underexpressed</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (1)</td>
<td valign="top" align="left">C4M061</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">39</td>
<td valign="top" align="center">31</td>
<td valign="top" align="center">40357/6.2</td>
</tr>
<tr>
<td valign="top" align="left">F-box/WD domain containing protein (2)</td>
<td valign="top" align="left">C4LUA3</td>
<td valign="top" align="center">7.87</td>
<td valign="top" align="center">39</td>
<td valign="top" align="center">18</td>
<td valign="top" align="center">84985/7.98</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (3)</td>
<td valign="top" align="left">C4LZE3</td>
<td valign="top" align="center">2.45</td>
<td valign="top" align="center">29</td>
<td valign="top" align="center">15</td>
<td valign="top" align="center">56661/6.99</td>
</tr>
<tr>
<td valign="top" align="left">Pyruvate, phosphate dikinase (4)</td>
<td valign="top" align="left">Q24801</td>
<td valign="top" align="center">2.72</td>
<td valign="top" align="center">53</td>
<td valign="top" align="center">39</td>
<td valign="top" align="center">97899/5.89</td>
</tr>
<tr>
<td valign="top" align="left">Cysteinyl-tRNA synthetase, putative (5)</td>
<td valign="top" align="left">C4M8V1</td>
<td valign="top" align="center">2.34</td>
<td valign="top" align="center">40</td>
<td valign="top" align="center">16</td>
<td valign="top" align="center">80198/7.24</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (7)</td>
<td valign="top" align="left">C4LWP4</td>
<td valign="top" align="center">2.78</td>
<td valign="top" align="center">30</td>
<td valign="top" align="center">22</td>
<td valign="top" align="center">22832/6.7</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (8)</td>
<td valign="top" align="left">C4LZ44</td>
<td valign="top" align="center">2.32</td>
<td valign="top" align="center">29</td>
<td valign="top" align="center">14</td>
<td valign="top" align="center">35973/5.95</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (9)</td>
<td valign="top" align="left">C4M9A0</td>
<td valign="top" align="center">2.8</td>
<td valign="top" align="center">34</td>
<td valign="top" align="center">45</td>
<td valign="top" align="center">13421/6.05</td>
</tr>
<tr>
<td valign="top" align="left">Tyrosine kinase, putative (10)</td>
<td valign="top" align="left">C4M315</td>
<td valign="top" align="center">6.08</td>
<td valign="top" align="center">34</td>
<td valign="top" align="center">17</td>
<td valign="top" align="center">125598/4.77</td>
</tr>
<tr>
<td valign="top" align="left">PCI domain containing protein (11)</td>
<td valign="top" align="left">C4M536</td>
<td valign="top" align="center">3.73</td>
<td valign="top" align="center">30</td>
<td valign="top" align="center">19</td>
<td valign="top" align="center">36088/6.23</td>
</tr>
<tr>
<td valign="top" align="left">Adapter protein (AP) family protein (13)</td>
<td valign="top" align="left">C4M5F2</td>
<td valign="top" align="center">2.81</td>
<td valign="top" align="center">37</td>
<td valign="top" align="center">7</td>
<td valign="top" align="center">98994/7.12</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (16)</td>
<td valign="top" align="left">C4M4Z1</td>
<td valign="top" align="center">2.07</td>
<td valign="top" align="center">29</td>
<td valign="top" align="center">24</td>
<td valign="top" align="center">27087/8.6</td>
</tr>
<tr>
<td valign="top" align="left">Fumarate hydratase class I, anaerobic, putative (17)</td>
<td valign="top" align="left">C4MB76</td>
<td valign="top" align="center">2.51</td>
<td valign="top" align="center">42</td>
<td valign="top" align="center">32</td>
<td valign="top" align="center">22311/7.09</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>IP (isoelectric point) and molecular weight were calculated using the EXPASY software (<uri xlink:href="https://web.expasy.org/compute_pi/">https://web.expasy.org/compute_pi/</uri>).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Identification of <italic>E. histolytica</italic> proteins that are modulated by QdNO T-017.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Protein (Spot number)</th>
<th valign="top" align="center">Accession number</th>
<th valign="top" align="center">Fold change</th>
<th valign="top" align="center">Mascot score</th>
<th valign="top" align="center">Sequence coverage %</th>
<th valign="top" align="center">Molecular weight (kDa)/IP</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" colspan="6" align="left">
<bold>Overexpressed</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">Rab GTPase (1)</td>
<td valign="top" align="left">Q5NT06</td>
<td valign="top" align="center">6.42</td>
<td valign="top" align="center">32</td>
<td valign="top" align="center">19</td>
<td valign="top" align="center">21448/5.32</td>
</tr>
<tr>
<td valign="top" align="left">60S ribosomal protein L27, putative (3)</td>
<td valign="top" align="left">C4M727</td>
<td valign="top" align="center">2.48</td>
<td valign="top" align="center">39</td>
<td valign="top" align="center">42</td>
<td valign="top" align="center">15758/10.44</td>
</tr>
<tr>
<td valign="top" align="left">Thioredoxin, putative (4)</td>
<td valign="top" align="left">C4LSU6</td>
<td valign="top" align="center">2.86</td>
<td valign="top" align="center">45</td>
<td valign="top" align="center">54</td>
<td valign="top" align="center">14811/6.58</td>
</tr>
<tr>
<td valign="top" align="left">Ribosome biogenesis protein, putative (5)</td>
<td valign="top" align="left">C4LVY6</td>
<td valign="top" align="center">5.48</td>
<td valign="top" align="center">32</td>
<td valign="top" align="center">17</td>
<td valign="top" align="center">36895/9.75</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (9)</td>
<td valign="top" align="left">C4M091</td>
<td valign="top" align="center">2.87</td>
<td valign="top" align="center">40</td>
<td valign="top" align="center">61</td>
<td valign="top" align="center">13913/7.61</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (13)</td>
<td valign="top" align="left">C4M630</td>
<td valign="top" align="center">1.86</td>
<td valign="top" align="center">40</td>
<td valign="top" align="center">39</td>
<td valign="top" align="center">36797/9.43</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (15)</td>
<td valign="top" align="left">B1N2U7</td>
<td valign="top" align="center">4.36</td>
<td valign="top" align="center">40</td>
<td valign="top" align="center">52</td>
<td valign="top" align="center">11306/5.05</td>
</tr>
<tr>
<td valign="top" align="left">AIG1 family protein (17)</td>
<td valign="top" align="left">B1N4J0</td>
<td valign="top" align="center">3.25</td>
<td valign="top" align="center">48</td>
<td valign="top" align="center">12</td>
<td valign="top" align="center">35560/5.09</td>
</tr>
<tr>
<td valign="top" align="left">ADP-ribosylation factor 1, putative (19)</td>
<td valign="top" align="left">Q1EQ60</td>
<td valign="top" align="center">2.79</td>
<td valign="top" align="center">36</td>
<td valign="top" align="center">37</td>
<td valign="top" align="center">19512/5.29</td>
</tr>
<tr>
<td valign="top" align="left">Grainin, putative (20)</td>
<td valign="top" align="left">B1N4A1</td>
<td valign="top" align="center">2.47</td>
<td valign="top" align="center">40</td>
<td valign="top" align="center">52</td>
<td valign="top" align="center">24599/6.73</td>
</tr>
<tr>
<td valign="top" colspan="6" align="left">
<bold>Underexpressed</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (1)</td>
<td valign="top" align="left">C4M061</td>
<td valign="top" align="center">2.28</td>
<td valign="top" align="center">39</td>
<td valign="top" align="center">31</td>
<td valign="top" align="center">40357/6.2</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (3)</td>
<td valign="top" align="left">C4M3S7</td>
<td valign="top" align="center">2.14</td>
<td valign="top" align="center">40</td>
<td valign="top" align="center">9</td>
<td valign="top" align="center">75471/6.78</td>
</tr>
<tr>
<td valign="top" align="left">Pyruvate phosphate dikinase (4)</td>
<td valign="top" align="left">Q24801</td>
<td valign="top" align="center">2.77</td>
<td valign="top" align="center">53</td>
<td valign="top" align="center">39</td>
<td valign="top" align="center">97899/5.89</td>
</tr>
<tr>
<td valign="top" align="left">Adenylylcyclase-associated protein, putative (5)</td>
<td valign="top" align="left">B1N3T9</td>
<td valign="top" align="center">6.06</td>
<td valign="top" align="center">31</td>
<td valign="top" align="center">28</td>
<td valign="top" align="center">18449/5.05</td>
</tr>
<tr>
<td valign="top" align="left">F-box/WD domain containing protein (6)</td>
<td valign="top" align="left">C4LUA3</td>
<td valign="top" align="center">3.63</td>
<td valign="top" align="center">39</td>
<td valign="top" align="center">18</td>
<td valign="top" align="center">84985/7.98</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (7)</td>
<td valign="top" align="left">C4M9A0</td>
<td valign="top" align="center">3.51</td>
<td valign="top" align="center">34</td>
<td valign="top" align="center">45</td>
<td valign="top" align="center">13421/6.05</td>
</tr>
<tr>
<td valign="top" align="left">Adapter protein (AP) family protein (11)</td>
<td valign="top" align="left">C4M5F2</td>
<td valign="top" align="center">3.44</td>
<td valign="top" align="center">37</td>
<td valign="top" align="center">7</td>
<td valign="top" align="center">98994/7.12</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (12)</td>
<td valign="top" align="left">C4M3R3</td>
<td valign="top" align="center">2.22</td>
<td valign="top" align="center">34</td>
<td valign="top" align="center">17</td>
<td valign="top" align="center">62.140/8.8</td>
</tr>
<tr>
<td valign="top" align="left">Importin beta-3 family protein (13)</td>
<td valign="top" align="left">C4LXC2</td>
<td valign="top" align="center">2.95</td>
<td valign="top" align="center">30</td>
<td valign="top" align="center">6</td>
<td valign="top" align="center">125550/5.1</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (17)</td>
<td valign="top" align="left">C4M563</td>
<td valign="top" align="center">3.68</td>
<td valign="top" align="center">42</td>
<td valign="top" align="center">19</td>
<td valign="top" align="center">123240/8.51</td>
</tr>
<tr>
<td valign="top" align="left">Cysteinyl-tRNA synthetase, putative (18)</td>
<td valign="top" align="left">C4M8V1</td>
<td valign="top" align="center">2.10</td>
<td valign="top" align="center">59</td>
<td valign="top" align="center">18</td>
<td valign="top" align="center">80198/7.24</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>IP (isoelectric point) and molecular weight were calculated using the EXPASY software (<uri xlink:href="https://web.expasy.org/compute_pi/">https://web.expasy.org/compute_pi/</uri>).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>mRNA expression in <italic>E. histolytica</italic> trophozoites under the effect of T-001 or T-017. Trophozoites were treated with T-001 or T-017 during 48&#xa0;h. Total RNAs were obtained and qRT-PCR was performed using Sensi FAST SYBR Hi-ROX master mix (Bioline), and specific primers to amplifying <bold>(A)</bold> Peroxiredoxin, <bold>(B)</bold> Tyrosine kinase, <bold>(C)</bold> Thioredoxin, <bold>(D)</bold> Adapter protein and <bold>(E)</bold> Cysteinyl-tRNA synthetase, as well as RNA Pol lI as endogenous control gene. Relative fold increase in gene expression was obtained using the &#x394;&#x394;CT method. Data corresponds to mean &#xb1; SD, of three independent experiments. Statistically significant differences in mRNA expression were analyzed using a Tukey test method with Sigma Stat statistical software ver.2.0. p &#x2264; 0.01 (**), p &#x2264; 0.001 (***).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-12-887647-g002.tif"/>
</fig>
<sec id="s3_1">
<title>Treatments With QdNOs T-001 and T-017 Modulate Proteins Involved in Various Biological Processes in Trophozoites of <italic>E. histolytica</italic>
</title>
<p>To categorize the function of the modulated proteins, the DAVID Bioinformatics Resources 6.8 bionformatic program (<uri xlink:href="https://david.ncifcrf.gov/">https://david.ncifcrf.gov/</uri>) and the PantherDB database (<uri xlink:href="http://www.pantherdb.org/">http://www.pantherdb.org/</uri>) were used. Those proteins whose function was not found were searched in the Argot 2 program (Functional annotation of proteins using the semantic similarity in the Gene Ontology). <xref ref-type="table" rid="T3">
<bold>Table&#xa0;3</bold>
</xref> shows the function of proteins deregulated by compound T-001. Interestingly, these include proteins related with translation (guanine nucleotide-binding protein subunit beta 2-like 1, 40S ribosomal protein S24 and cysteinyl-tRNA synthetase), intracellular traffic (TBC domain containing protein, vesicle-fusing ATPase and adapter protein), phosphorylation (hypothetical protein [3] and [16], and tyrosine kinase), cytoskeletal organization (actin 2 and calmodulin), energy generation (pyruvate phosphate dikinase and fumarate hydratase class I), nucleic acid binding (hypothetical protein [8] and PCI domain containing protein), redox homeostasis (peroxiredoxin), stress response (truncated hsp70 family protein), ubiquitination (hypothetical protein [12]), kinase activity (hypothetical protein [1]), transport (hypothetical protein [7]) and proteins with unknown function (hypothetical proteins [9] and [18], and F-box/WD domain containing protein). On the other hand, proteins deregulated by compound T-017 were related with intracellular traffic (Rab GTPase family protein, ADP-ribosylation factor 1, importin beta-3 family protein and adapter protein), nucleic acid binding (hypothetical protein [9] and [1]), translation (60S ribosomal protein L27 and cysteinyl-tRNA synthetase), binding to calcium ion (grainin), hydrolase activity (hypothetical protein [15]), redox homeostasis (thioredoxin), rRNA processing (ribosome biogenesis protein), stress response (AIG1 family protein), energy generation (pyruvate phosphate dikinase), post-traslational modifications (hypothetical protein [17]), cytoskeletal organization (adenylylcyclase-associated protein), post-transcriptional processing (hypothetical protein [12]) and proteins with unknown function (hypothetical protein [3], [7] and [13], and F-box/WD domain containing protein) (<xref ref-type="table" rid="T4">
<bold>Table&#xa0;4</bold>
</xref>).</p>
<table-wrap id="T3" position="float">
<label>Table&#xa0;3</label>
<caption>
<p>Functional categorization of <italic>E. histolytica</italic> proteins modulated by treatment with T-001.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Protein (Spot number)</th>
<th valign="top" align="center">Amoeba BD number</th>
<th valign="top" align="center">Function</th>
<th valign="top" align="center">Localization</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" colspan="4" align="left">
<bold>Overexpressed</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">Actin 2 protein, putative (1)</td>
<td valign="top" align="left">EHI_161200</td>
<td valign="top" align="left">Cytoskeletal organization</td>
<td valign="top" align="left">Actin Cytoskeleton</td>
</tr>
<tr>
<td valign="top" align="left">Calmodulin, putative(19)</td>
<td valign="top" align="left">EHI_044820</td>
<td valign="top" align="left">Cytoskeletal organization</td>
<td valign="top" align="left">Cytoplasm</td>
</tr>
<tr>
<td valign="top" align="left">TBC domain containing protein</td>
<td valign="top" align="left">EHI_091080</td>
<td valign="top" align="left">Intracellular traffic</td>
<td valign="top" align="left">Membrane</td>
</tr>
<tr>
<td valign="top" align="left">Vesicle-fusing ATPase (9)</td>
<td valign="top" align="left">EHI_004640</td>
<td valign="top" align="left">Intracellular traffic</td>
<td valign="top" align="left">Cytoplasm</td>
</tr>
<tr>
<td valign="top" align="left">Guanine nucleotide-binding protein subunit beta 2-like 1, putative (2)</td>
<td valign="top" align="left">EHI_171280</td>
<td valign="top" align="left">Traslation</td>
<td valign="top" align="left">Cytoplasm, nucleus</td>
</tr>
<tr>
<td valign="top" align="left"> 40S ribosomal protein S24, putative(10)</td>
<td valign="top" align="left">EHI_148820</td>
<td valign="top" align="left">Traslation</td>
<td valign="top" align="left">Cytoplasm</td>
</tr>
<tr>
<td valign="top" align="left">Protein phosphatase, putative (14)</td>
<td valign="top" align="left">EHI_110320</td>
<td valign="top" align="left">Phosphatase activity</td>
<td valign="top" align="left">Membrane</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (18)</td>
<td valign="top" align="left">EHI_153630</td>
<td valign="top" align="left">Unknown function</td>
<td valign="top" align="left">Membrane</td>
</tr>
<tr>
<td valign="top" align="left">Peroxiredoxin, putative (17)</td>
<td valign="top" align="left">EHI_121620</td>
<td valign="top" align="left">Cell redox homeostasis</td>
<td valign="top" align="left">Cytoplasm</td>
</tr>
<tr>
<td valign="top" align="left">Truncated hsp70 family protein (3)</td>
<td valign="top" align="left">EHI_147220</td>
<td valign="top" align="left">Stress response</td>
<td valign="top" align="left">Cytoplasm</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (12)</td>
<td valign="top" align="left">EHI_076020</td>
<td valign="top" align="left">Protein ubiquitination</td>
<td valign="top" align="left">Membrane</td>
</tr>
<tr>
<td valign="top" colspan="4" align="left">
<bold>Underexpressed</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (3)</td>
<td valign="top" align="left">EHI_137800</td>
<td valign="top" align="left">Protein phosphorylation</td>
<td valign="top" align="left">Membrane</td>
</tr>
<tr>
<td valign="top" align="left">Tyrosine kinase, putative (10)</td>
<td valign="top" align="left">EHI_025280</td>
<td valign="top" align="left">Protein phosphorylation</td>
<td valign="top" align="left">Membrane</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (16)</td>
<td valign="top" align="left">EHI_035240</td>
<td valign="top" align="left">Protein phosphorylation</td>
<td valign="top" align="left">Cytoplasm</td>
</tr>
<tr>
<td valign="top" align="left">F-box/WD domain containing protein (2)</td>
<td valign="top" align="left">EHI_110540</td>
<td valign="top" align="left">Unknown function</td>
<td valign="top" align="left">Cytoplasm</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (9)</td>
<td valign="top" align="left">EHI_074500</td>
<td valign="top" align="left">Unknown function</td>
<td valign="top" align="left">Membrane</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (8)</td>
<td valign="top" align="left">EHI_009700</td>
<td valign="top" align="left">Nucleic acid binding</td>
<td valign="top" align="left">No Found</td>
</tr>
<tr>
<td valign="top" align="left">PCI domain containing protein (11)</td>
<td valign="top" align="left">EHI_078210</td>
<td valign="top" align="left">Nucleic acid binding</td>
<td valign="top" align="left">Cytoplasm, nucleus</td>
</tr>
<tr>
<td valign="top" align="left">Pyruvate, phosphate dikinase (4)</td>
<td valign="top" align="left">EHI_009530</td>
<td valign="top" align="left">Energy generation (glycolysis)</td>
<td valign="top" align="left">Cytoplasm</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (1)</td>
<td valign="top" align="left">EHI_021470</td>
<td valign="top" align="left">Kinase activity</td>
<td valign="top" align="left">Membrane</td>
</tr>
<tr>
<td valign="top" align="left">Cysteinyl-tRNA synthetase, putative (5)</td>
<td valign="top" align="left">EHI_169700</td>
<td valign="top" align="left">Cysteinyl-tRNA aminoacylation (translation)</td>
<td valign="top" align="left">Cytoplasm</td>
</tr>
<tr>
<td valign="top" align="left">Fumarate hydratase class I, anaerobic, putative (17)</td>
<td valign="top" align="left">EHI_117270</td>
<td valign="top" align="left">Generation of precursor metabolites and energy</td>
<td valign="top" align="left">Cytoplasm</td>
</tr>
<tr>
<td valign="top" align="left">Adapter protein (AP) family protein (13)</td>
<td valign="top" align="left">EHI_058450</td>
<td valign="top" align="left">Intracellular traffic</td>
<td valign="top" align="left">Cytoplasm</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (7)</td>
<td valign="top" align="left">EHI_069560</td>
<td valign="top" align="left">Transport</td>
<td valign="top" align="left">Membrane</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T4" position="float">
<label>Table&#xa0;4</label>
<caption>
<p>Functional categorization of <italic>E. histolytica</italic> proteins modulated by treatment with T-017.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Protein (Spot number)</th>
<th valign="top" align="center">Amoeba BD number</th>
<th valign="top" align="center">Function</th>
<th valign="top" align="center">Localization</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" colspan="4" align="left">
<bold>Overexpressed</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">Rab GTPase family (1)</td>
<td valign="top" align="left">EHI_096440</td>
<td valign="top" align="left">Intracellular traffic</td>
<td valign="top" align="left">Cell</td>
</tr>
<tr>
<td valign="top" align="left">ADP-ribosylation factor 1, putative (19)</td>
<td valign="top" align="left">EHI_121870</td>
<td valign="top" align="left">Intracellular traffic</td>
<td valign="top" align="left">Cytoplasm</td>
</tr>
<tr>
<td valign="top" align="left">Grainin, putative (20)</td>
<td valign="top" align="left">EHI_120360</td>
<td valign="top" align="left">Binding to calcium ions</td>
<td valign="top" align="left">Cytoplasm</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (9)</td>
<td valign="top" align="left">EHI_004970</td>
<td valign="top" align="left">Nucleic acid binding</td>
<td valign="top" align="left">No found</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (15)</td>
<td valign="top" align="left">EHI_159530</td>
<td valign="top" align="left">Hydrolase activity</td>
<td valign="top" align="left">Membrane</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (13)</td>
<td valign="top" align="left">EHI_125400</td>
<td valign="top" align="left">Unknown function</td>
<td valign="top" align="left">Membrane</td>
</tr>
<tr>
<td valign="top" align="left">Thioredoxin, putative (4)</td>
<td valign="top" align="left">EHI_152600</td>
<td valign="top" align="left">Redox homeostasis</td>
<td valign="top" align="left">Cell</td>
</tr>
<tr>
<td valign="top" align="left">Ribosome biogenesis protein, putative (5)</td>
<td valign="top" align="left">EHI_126010</td>
<td valign="top" align="left">rRNA processing</td>
<td valign="top" align="left">Nucleus</td>
</tr>
<tr>
<td valign="top" align="left">AIG1 family protein (17)</td>
<td valign="top" align="left">EHI_067730</td>
<td valign="top" align="left">Stress response</td>
<td valign="top" align="left">Membrane</td>
</tr>
<tr>
<td valign="top" align="left">60S ribosomal protein L27, putative (3)</td>
<td valign="top" align="left">EHI_183480</td>
<td valign="top" align="left">Translation</td>
<td valign="top" align="left">Cell component (ribosomal subunit)</td>
</tr>
<tr>
<td valign="top" colspan="4" align="left">
<bold>Underexpressed</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">Importin beta-3 family protein (13)</td>
<td valign="top" align="left">EHI_098400</td>
<td valign="top" align="left">Intracellular traffic</td>
<td valign="top" align="left">Cytoplasm; nucleus</td>
</tr>
<tr>
<td valign="top" align="left">Adapter protein (AP) family protein (11)</td>
<td valign="top" align="left">EHI_058450</td>
<td valign="top" align="left">Intracellular traffic</td>
<td valign="top" align="left">Cytoplasm</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (7)</td>
<td valign="top" align="left">EHI_074500</td>
<td valign="top" align="left">Unknown function</td>
<td valign="top" align="left">Membrane</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (3)</td>
<td valign="top" align="left">EHI_052890</td>
<td valign="top" align="left">Unknown function</td>
<td valign="top" align="left">Membrane</td>
</tr>
<tr>
<td valign="top" align="left">F-box/WD domain containing protein (6)</td>
<td valign="top" align="left">EHI_110540</td>
<td valign="top" align="left">Unknown function</td>
<td valign="top" align="left">Membrane</td>
</tr>
<tr>
<td valign="top" align="left">Pyruvate phosphate dikinase (4)</td>
<td valign="top" align="left">EHI_009530</td>
<td valign="top" align="left">Catalytic activity</td>
<td valign="top" align="left">No found</td>
</tr>
<tr>
<td valign="top" align="left">Cysteinyl-tRNA synthetase, putative (18)</td>
<td valign="top" align="left">EHI_169700</td>
<td valign="top" align="left">Cysteinyl-tRNA aminoacylation</td>
<td valign="top" align="left">Cytoplasm</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (17)</td>
<td valign="top" align="left">EHI_178100</td>
<td valign="top" align="left">Post-translational modification</td>
<td valign="top" align="left">Membrane</td>
</tr>
<tr>
<td valign="top" align="left">Adenylylcyclase-associated protein, putative (5)</td>
<td valign="top" align="left">EHI_081430</td>
<td valign="top" align="left">Cytoskeletal organization</td>
<td valign="top" align="left">Actin cytoskeleton</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (12)</td>
<td valign="top" align="left">EHI_146210</td>
<td valign="top" align="left">post-transcriptional processing</td>
<td valign="top" align="left">No found</td>
</tr>
<tr>
<td valign="top" align="left">Hypothetical protein (1)</td>
<td valign="top" align="left">EHI_021470</td>
<td valign="top" align="left">Nucleic acid binding</td>
<td valign="top" align="left">Membrane</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Interestingly, both quinoxaline derivatives affect proteins that participate in the dynamics of the actin cytoskeleton and intracellular trafficking. Notably, Actin 2 and calmodulin overexpression was evidenced in trophozoites treated with T-001, while the protein associated with adenylyl cyclase were found to be downregulated by T-017. On the other hand, proteins associated with trafficking as TBC domain containing protein, vesicle-fusing ATPase and adapter protein were deregulated by compound T-001, while T-017 deregulated Rab GTPase family protein, ADP-ribosylation factor 1, importin beta-3 family protein and adapter protein. The cytoskeleton is particularly relevant for the pathogenicity mechanisms of amoeba. Adhesion is one of the first steps in the pathogenesis of <italic>E. histolytica</italic> and a prerequisite for host cell destruction. Together with the motility and ability to engulf host cells, adhesion allows trophozoites to colonize, invade and destroy different human tissues. Therefore, we decided to evaluate the impact of T-001 and T-017 treatment on migration, phagocytosis, and adhesion in <italic>E. histolytica</italic>; changes in the cytopathic effect of this parasite were also evaluated.</p>
</sec>
<sec id="s3_2">
<title>T-001 and T-017 Decrease Migration, Adhesion and the Cytolytic Effect of <italic>E. histolytica</italic> Trophozoites</title>
<p>To evaluate the effect of quinoxaline derivatives on the migration of amoeba trophozoites, an assay was carried out using transwell chambers. The trophozoites treated with T-001 showed a decrease of 27.14% in their migration with respect to untreated amoebae; similarly, compound T-017 produced a 23.77% decrease in the migration of trophozoites (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3A</bold>
</xref>). Likewise, to evaluate if quinoxaline derivatives could affect the adhesion of ameba trophozoites, an assay was carried out to evaluate trophozoite adhesion to SW-480 cell cultures. As shown in <xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3B</bold>
</xref>, both compounds caused a reduction in trophozoites adhesion, being compound T-001 the one that produced the greatest effect with a reduction of 49% compared to untreated trophozoites, while compound T-017 reduced adhesion in 27%. To evidence whether the decrease in adhesion caused by T-001 and T-017 compounds could affect the cytolytic activity of the amoeba trophozoites, we carried out interaction tests between SW-480 cell cultures and trophozoites at 37&#xb0;C. After 45&#xa0;min of interaction with untreated trophozoites, cell cultures showed an average of 75.66% destruction (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3C</bold>
</xref>). Similarly, amoebae treated with 0.01% DMSO showed 71.33% cell destruction. On the contrary, trophozoites treated with T-001 caused a lower degree of damage, since they only produced 52.66% of destruction. However, T-017 treatment did not significantly affect the ability of trophozoites to destroy SW-480 cell monolayers, since trophozoites treated with T-017 produced 67.66% of cell destruction.</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Effect of T-001 and T-017 on migration <bold>(A)</bold>, adhesion <bold>(B)</bold> and cytolytic activity <bold>(C)</bold> of (<italic>E</italic>) <italic>histolytica</italic> trophozoites. Trophozoites were previously treated with T-001 or T-017 as described. <bold>(A)</bold> Trophozoite migration was determined after 3&#xa0;h incubation in transwell chambers and cell counting; migration was expressed as percentage. <bold>(B)</bold> Trophozoites were seeded on SW-480 epithelial cell monolayer during 15&#xa0;min, adhesion were determined and expressed as percentage. <bold>(C)</bold> SW-480 cell monolayers were incubated with <italic>E. histolytica</italic> trophozoites for 45&#xa0;min; damage to the SW-480 cell monolayer was evaluated by the release of the LDH enzyme to the culture medium and (absorbance at 492nm) expressed as percentage; the histogram shows the average percentage of destruction of the SW-480 monolayers. Trophozoites treated with DMSO 0.01% and grown in standard condition were used as controls. Graphs show the mean &#xb1; standard error of three independent experiments. The comparisons between groups were carried out with the one way ANOVA test, p &lt; 0.05 (*), p &lt; 0.01 (**), p &lt; 0.001 (***).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-12-887647-g003.tif"/>
</fig>
</sec>
<sec id="s3_3">
<title>T-001 and T-017 Affect Erythrophagocytosis of <italic>E. histolytica</italic>
</title>
<p>The effect of quinoxaline derivatives on the phagocytic capacity of amoeba trophozoites was carried out by interacting amoeba trophozoites with human erythrocytes. For this analysis, the number of erythrocytes ingested by amoeba trophozoites (previously treated with T-001 and T-017) was determined after 0, 5, 10 and 15&#xa0;min of interaction. The results were visualized through staining with diaminobenzidine. As shown in <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>, this is a time-dependent process in untreated trophozoites since there is a progressive increase in the number of ingested erythrocytes through time. Trophozoites treated with 0.01% DMSO presented no significant difference with respect to untreated trophozoites. Interestingly, in the case of T-001 treatment, the erythrophagocytosis rate was significantly decreased by 32% and 23% at 10 and 15 minutes of interaction, respectively in reference to untreated group. In contrast, T-017 treatment increased erythrophagocytosis by about 50% and 42% at the same interaction times, with respect to untreated trophozoites. (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4A</bold>
</xref>). These results were corroborated by measuring the hemoglobin contained in the trophozoites after ten minutes of interaction with red blood cells; as shown in <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4B</bold>
</xref>, the amount of hemoglobin was decreased by 30% and increased by 32%, in trophozoites treated with T-001 and T-017, respectively (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4B</bold>
</xref>).</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Erythrophagocytosis of <italic>E. histolytica</italic> trophozoites treated with T-001 and T-017. <bold>(A)</bold> Erythrophagocytosis rate at 0, 5, 10 and 15&#xa0;min of interaction of erythrocytes and trophozoites previously treated with T-001 and T-017. <bold>(B)</bold> Hemoglobin quantitation after 10&#xa0;min interaction of erythrocytes and trophozoites previously treated with T-001 and T-017 and untreated. Trophozoites treated with DMSO 0.01% and grown in standard condition were used as controls. Graphs show the mean &#xb1; standard error of three independent experiments. The comparisons between groups were carried out with the one way ANOVA test, p &lt; 0.05 (*) p &lt; 0.01 (**) p &lt; 0.001 (***).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-12-887647-g004.tif"/>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>QdNOs are a group of heterocyclic compounds characterized by a broad spectrum of biological activity. They are used as therapeutic agents in the treatment of various infections (<xref ref-type="bibr" rid="B21">Ishikawa et&#xa0;al., 2012</xref>; <xref ref-type="bibr" rid="B25">Lee et&#xa0;al., 2013</xref>; <xref ref-type="bibr" rid="B22">Kaplum et&#xa0;al., 2016</xref>) and inhibit the growth of protozoan parasites such as <italic>P. falciparum</italic> (IC50 = 1.25 &#xb5;M) (<xref ref-type="bibr" rid="B2">Aldana et&#xa0;al., 2003</xref>), <italic>P. falciparum</italic> FCR-3 sensitive to chloroquine (IC50 = 0.40 &#xb5;M) (<xref ref-type="bibr" rid="B5">Bonilla-Ramirez et&#xa0;al., 2018</xref>), <italic>L. amazonensis</italic> (IC50 = 0.74 &#xb5;M) (<xref ref-type="bibr" rid="B8">Chac&#xf3;n-Vargas et&#xa0;al., 2018</xref>), <italic>T. cruzi</italic> (IC50 = 2.42 &#xb5;M) (<xref ref-type="bibr" rid="B9">Chac&#xf3;n-Vargas et&#xa0;al., 2017</xref>), <italic>T. vaginalis</italic> (MIC = 0.39 &#xb5;g/mL) (<xref ref-type="bibr" rid="B7">Carta et&#xa0;al., 2004</xref>) and <italic>E. histolytica</italic> (<xref ref-type="bibr" rid="B42">Soto-S&#xe1;nchez et&#xa0;al., 2020</xref>). In order to contribute to the characterization of the antiamebic effect of two QdNOs with the highest inhibitory effect, in this work we analyzed the proteomic profile of <italic>E. histolytica</italic> trophozoites treated with T-001 and T-017 molecules and assessed the impact of deregulated proteins by functional assays.</p>
<p>The T-001 and T-017 QdNOs affect the abundance of 163 and 131 proteins, respectively. Among them, mass spectrometry assays allowed the identification of 24 proteins deregulated by T-001 (11 were found to be overexpressed and 13 under-expressed), while 10 over-expressed and 11 under expressed proteins were identified in T-017 treated parasites. The relative mRNA expression levels of genes corresponding to Peroxiredoxin, Tyrosine kinase, putative Thioredoxin, Adapter protein and Cysteinyl-tRNA synthetase agreed with the differential amount of these proteins in the presence of QdNOs, which validate the proteomic data. Although study of mRNA expression is not the best tool to validate protein expression, it is useful in microorganisms, such as <italic>E. histolytica</italic>, where there are no commercial antibodies to perform western blot assays.</p>
<p>Modulated proteins are associated with various cellular processes, such as intracellular trafficking, organization of the cytoskeleton and redox homeostasis, among others. Intracellular trafficking, including endocytosis and exocytosis, allows the transport of proteins and other macromolecules through organelles of the endomembrane system (<xref ref-type="bibr" rid="B20">Herman et&#xa0;al., 2017</xref>). Membrane trafficking interconnects the nuclear envelope, endoplasmic reticulum (ER), golgi apparatus, and various secretory vesicles. <italic>E. histolytica</italic> lacks visible classical organelles such as mitochondria and ER, although it has functions and proteins associated with Golgi/ER (<xref ref-type="bibr" rid="B10">Dacks et&#xa0;al., 2003</xref>; <xref ref-type="bibr" rid="B6">Bredeston et&#xa0;al., 2005</xref>; <xref ref-type="bibr" rid="B44">Teixeira and Huston, 2008</xref>). Additionally, the presence of continuous ER compartments has been suggested (<xref ref-type="bibr" rid="B44">Teixeira and Huston, 2008</xref>). Other studies support the existence of components of the trans Golgi network similar to those in mammals, but with a peculiar compartmentalization, also suggesting a very active membrane trafficking process (<xref ref-type="bibr" rid="B32">Perdomo et&#xa0;al., 2015</xref>). In trophozoites treated with quinoxalines T-001 and T-017, the expression of the adapter protein AP (C4M4Z1), which belongs to the family of AP-1, AP-2 and AP-3 involved in endosomal trafficking and endocytosis on the cell surface, was found to be decreased. Likewise, compound T-017 produced a decrease in the expression of putative beta 3 importin whose function has not yet been characterized in amoeba, however it is known that in other organisms this protein participates in the nuclear import of proteins that carry nuclear localization signals, through interactions with importin &#x3b1;, thus forming a trimeric complex (<xref ref-type="bibr" rid="B15">Gilchrist et&#xa0;al., 2002</xref>). Interestingly, the quinoxalines T-001 or T-017 also produced the overexpression of proteins of intracellular traffic: the protein with TBC domain (C4M7P5) and the protein of the Rab GTPase family (Q5NT06), both involved in the dynamics of the vesicular fusion (some Rabs contain the TBC domain), the ADP-ribosylation factor (ARFs) (Q1EQ60), a regulator of vesicle formation in intracellular traffic (<xref ref-type="bibr" rid="B40">Serbzhinskiy et&#xa0;al., 2015</xref>) and the putative vesicle-fusion ATPase (C4LYS4), which catalyzes the fusion of transport vesicles within the cisternae of the Golgi apparatus (<xref ref-type="bibr" rid="B35">Qiu, 2012</xref>). The deregulation of these proteins that participate in the intracellular traffic could explain the presence of a higher number of vacuoles and vesicles that we previously reported in <italic>E. histolytica</italic> trophozoites treated with T-001 and T-017 (<xref ref-type="bibr" rid="B42">Soto-S&#xe1;nchez et&#xa0;al, 2020</xref>). Other studies carried out in <italic>T. cruzi</italic> epimastigotes also evidenced that QdNOs produced an increase in the number of vesicles in the cytoplasm was also found, as well as alterations in the Golgi apparatus, which suggest that QdNOs alters the secretory pathway in this parasite (<xref ref-type="bibr" rid="B36">Rodrigues et&#xa0;al., 2014</xref>).</p>
<p>On the other hand, it has been documented that under conditions of oxidative stress, such as that produced by quinoxalines, there is an active commitment of the <italic>E. histolytica</italic> cytoskeleton to provide support for survival functions, that is, migration, adhesion, phagocytosis, etc. (<xref ref-type="bibr" rid="B34">Pineda and Perdomo, 2017</xref>). Our results coincide with this observation since trophozoites treated with quinoxalines had an increase in the expression of actin 2 (B1N5D1), putative calmodulin (C4LTA2) and the adenyl cyclase-associated protein (B1N3T9). The actin protein is essential for the functions of the cytoskeleton, being necessary for the modulation between its filamentous (F-actin) and globular (G-actin) forms (<xref ref-type="bibr" rid="B28">Manich et&#xa0;al., 2018</xref>). One of the proteins that control actin dynamics is adenylate cyclase (AC) (<xref ref-type="bibr" rid="B51">Zhang et&#xa0;al., 2013</xref>), whose G-protein-mediated activation leads to changes in actin structure and effect on adhesion and movement of trophozoites (<xref ref-type="bibr" rid="B41">Soid-Raggi et&#xa0;al., 1998</xref>). Regarding the calmodulin-like protein, even though this typical protein has not been seen in <italic>E. histolytica</italic>, it has a large number of Ca<sup>2+</sup> binding proteins, some of which can bind directly to actin and modulate its dynamics, a phenomenon that has not been seen in any other system (<xref ref-type="bibr" rid="B4">Babuta et&#xa0;al., 2020</xref>). It is likely that the overexpression of these proteins explains the alterations observed in the functionality of the cytoskeleton in trophozoites treated with T-001 and T-017, namely a decreased migration, adhesion and cytolysis, as well as alterations in erythrophagocytosis.</p>
<p>Previous works reported that quinoxaline derivatives inhibit enzymes that counteract oxidative stress, such as trypanothion reductase in <italic>Trypanosoma cruzi</italic> (<xref ref-type="bibr" rid="B9">Chac&#xf3;n-Vargas et&#xa0;al., 2017</xref>) and peroxiredoxin in <italic>Toxoplasma gondii</italic> (<xref ref-type="bibr" rid="B19">Haraldsen et&#xa0;al., 2009</xref>).</p>
<p>Quinoxaline-induced oxidative stress also affects enzyme systems in amoeba. In a previous study, we demonstrated that QdNOs T-001 and T-017 induced oxidative stress and inhibition of amoeba thioredoxin reductase (EhTrxR) activity (<xref ref-type="bibr" rid="B42">Soto-S&#xe1;nchez et&#xa0;al., 2020</xref>). In the present work, we found that the expression of thioredoxin (C4LSU6) is upregulated in trophozoites treated with T-001; this supports the effect of quinoxalines on the thioredoxin-thioredoxin reductase system, which participates in the amoeba antioxidant defense, protecting sensitive proteins against oxidative stress (<xref ref-type="bibr" rid="B39">Schlosser et&#xa0;al., 2013</xref>). In this system, electrons are transferred from NADPH <italic>via</italic> FAD to the active disulfide site of TrxR, which reduces thioredoxin. Reduced thioredoxin interacts with target proteins involved in various biological processes, such as the degradation of reactive oxygen species (<xref ref-type="bibr" rid="B3">Andrade and Reed, 2015</xref>). Additionally, peroxiredoxin, an antioxidant protein that interacts with thioredoxin in its reduced state, was also found to be more abundant in trophozoites treated with T-017. Peroxiredoxin reduces peroxides, such as H<sub>2</sub>O<sub>2</sub>, hydroperoxides, and peroxynitrites, using thioredoxin and its dithiol motif as the hydrogen donor, thereby establishing the enzymatic redox cascade that mediates the flow of electrons from NADPH to TrxR and then to the thioredoxin. The reduced form of thioredoxin is then able to interact with peroxiredoxin (<xref ref-type="bibr" rid="B18">Gwairgi and Ghildyal, 2018</xref>). <italic>In vitro</italic>, an increase in the levels of the peroxiredoxin gene of <italic>E. histolytica</italic> HM1: IMSS has been seen in response to an environment with high oxygen content (<xref ref-type="bibr" rid="B1">Akbar et&#xa0;al., 2004</xref>). It is also known that <italic>E. histolytica</italic> moderately increases peroxiredoxin mRNA levels when it is incubated with 50 &#x3bc;M of metronidazole which, during its reoxidation, generates reactive oxygen species (<xref ref-type="bibr" rid="B43">Tazreiter et&#xa0;al., 2008</xref>).</p>
<p>Even though both compounds show antiamoebic activity, modulating proteins that participate in common events and impacting on similar pathogenicity mechanisms, there are clear differences in the modulated proteins, as well as in the degree of impact they have on the parasite. Compounds T-001 and T-017 differ in having a methyl group or a benzyl group in the R2 position of the quinoxaline ring, respectively, which suggests that these compounds may be interacting differently with their potential molecular targets, producing variations in their biological effect. In a previous study using molecular docking, we evaluated the interaction of T-001 and T-017 with thioredoxin reductase from <italic>E. histolytica</italic>, finding that structure affects binding energy and interactions with amino acids of the redox active site and/or the NADPH binding site; In addition, it was also found that quinoxalines with different substituents in the R2 position and with an increase in the aliphatic chain in the R3 position of the quinoxaline ring produced different changes in the morphology and ultrastructure of the amoeba trophozoite (<xref ref-type="bibr" rid="B42">Soto-S&#xe1;nchez et&#xa0;al., 2020</xref>). Thus, the structural differences between T-001 and T-017 may explain the differences in their antiamoebic effect.</p>
<p>Altogether, our results indicate that the quinoxaline derivatives T-001 and T-017 exert their antiamebic activity by modulating the expression of proteins related with various mechanisms, such as intracellular traffic, organization of the cytoskeleton and redox homeostasis, among others, which impact on basic trophozoite functions, including migration, adhesion, cytolysis and phagocytic capacity, that eventually leading to the death of the parasite.</p>
</sec>
<sec id="s5" sec-type="data-availability">
<title>Data Availability Statement</title>
<p>The datasets presented in this study can be found in online repositories. The name of the repository and accession number can be found below: PRIDE, ProteomeXchange; PXD032322.</p>
</sec>
<sec id="s6" sec-type="author-contributions">
<title>Author Contributions</title>
<p>RA-B: Real-time qRT-PCR, data collection, analysis, interpretation and writing of the article. AL-S: <italic>E. histolytica</italic> culture and treatments, obtaining mRNA. JS-S: 2D-DIGE and function analysis. LM: data interpretation, critical writing and revision of the article. GR: quinoxaline synthesis, OM-C: Mass spectrometry analysis. ER-M: project proposal and design, data interpretation, writing of the article. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="s7" sec-type="funding-information">
<title>Funding</title>
<p>This work was supported by the Secretar&#xed;a de Investigaci&#xf3;n y Posgrado, Instituto Polit&#xe9;cnico Nacional (SIP-IPN)-Mexico (projects 20200335, 20211108). RGAB received financial support through the scholarship 285467 granted by SEP/CONACYT-Mexico. ER-M, LM and GR received supports from COFAA-IPN, EDI-IPN and SNI-CONACyT. AL-S received a BEIFI-IPN support and CONACYT fellowship (CVU1008704).</p>
</sec>
<sec id="s8" sec-type="COI-statement">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s9" sec-type="disclaimer">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We thank Dr. &#xc1;ngel Ba&#xf1;uelos Hern&#xe1;ndez and Dr. Jonnatan Pais Morales for its comments and technical assistance during the project.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akbar</surname> <given-names>M. A.</given-names>
</name>
<name>
<surname>Chatterjee</surname> <given-names>N. S.</given-names>
</name>
<name>
<surname>Sen</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Debnath</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Pal</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Bera</surname> <given-names>T.</given-names>
</name>
<etal/>
</person-group>. (<year>2004</year>). <article-title>Genes Induced by a High-Oxygen Environment in Entamoeba Histolytica</article-title>. <source>Mol. Biochem. Parasitol.</source> <volume>133</volume> (<issue>2</issue>), <fpage>187</fpage>&#x2013;<lpage>196</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.molbiopara.2003.10.006</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aldana</surname> <given-names>I.</given-names>
</name>
<name>
<surname>Ortega</surname> <given-names>M. A.</given-names>
</name>
<name>
<surname>Jaso</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Zarranz</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Oporto</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Gimenez</surname> <given-names>A.</given-names>
</name>
<etal/>
</person-group>. (<year>2003</year>). <article-title>Anti-Malarial Activity of Some 7-Chloro-2-Quinoxalinecarbonitrile-1, 4-Di-N-Oxide Derivatives</article-title>. <source>Die Pharmazie</source> <volume>58</volume> (<issue>1</issue>), <fpage>68</fpage>&#x2013;<lpage>69</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/CHIN.200321220</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andrade</surname> <given-names>R. M.</given-names>
</name>
<name>
<surname>Reed</surname> <given-names>S. L.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>New Drug Target in Protozoan Parasites: The Role of Thioredoxin Reductase</article-title>. <source>Front. Microbiol.</source> <volume>6</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fmicb.2015.00975</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Babuta</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Bhattacharya</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Bhattacharya</surname> <given-names>A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Entamoeba Histolytica and Pathogenesis: A Calcium Connection</article-title>. <source>PloS Pathog.</source> <volume>16</volume> (<issue>5</issue>), <elocation-id>e1008214</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.ppat.1008214</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonilla-Ramirez</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Rios</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Quiliano</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Ramirez-Calderon</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Beltr&#xe1;n-Hortelano</surname> <given-names>I.</given-names>
</name>
<name>
<surname>Franetich</surname> <given-names>J. F.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>Novel Antimalarial Chloroquine-and Primaquine-Quinoxaline 1, 4-Di-N-Oxide Hybrids: Design, Synthesis, Plasmodium Life Cycle Stage Profile, and Preliminary Toxicity Studies</article-title>. <source>Eur. J. Medicinal Chem.</source> <volume>158</volume>, <fpage>68</fpage>&#x2013;<lpage>81</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ejmech.2018.08.063</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bredeston</surname> <given-names>L. M.</given-names>
</name>
<name>
<surname>Caffaro</surname> <given-names>C. E.</given-names>
</name>
<name>
<surname>Samuelson</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Hirschberg</surname> <given-names>C. B.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Golgi and Endoplasmic Reticulum Functions Take Place in Different Subcellular Compartments of Entamoeba Histolytica</article-title>. <source>J. Biol. Chem.</source> <volume>280</volume> (<issue>37</issue>), <fpage>32168</fpage>&#x2013;<lpage>32176</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1074/jbc.M507035200</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carta</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Loriga</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Paglietti</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Mattana</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Fiori</surname> <given-names>P. L.</given-names>
</name>
<name>
<surname>Mollicotti</surname> <given-names>P.</given-names>
</name>
<etal/>
</person-group>. (<year>2004</year>). <article-title>Synthesis, Anti-Mycobacterial, Anti-Trichomonas and Anti-Candida <italic>In Vitro</italic> Activities of 2-Substituted-6,7-Difluoro-3-Methylquinoxaline 1,4-Dioxides</article-title>. <source>Eur. J. Medicinal Chem.</source> <volume>39</volume> (<issue>2</issue>), <fpage>195</fpage>&#x2013;<lpage>203</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ejmech.2003.11.008</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chac&#xf3;n-Vargas</surname> <given-names>K. F.</given-names>
</name>
<name>
<surname>Andrade-Ochoa</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Nogueda-Torres</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Ju&#xe1;rez-Ram&#xed;rez</surname> <given-names>D. C.</given-names>
</name>
<name>
<surname>Lara-Ram&#xed;rez</surname> <given-names>E. E.</given-names>
</name>
<name>
<surname>Mondrag&#xf3;n-Flores</surname> <given-names>R.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>Isopropyl Quinoxaline-7-Carboxylate 1,4-Di-N-Oxide Derivatives Induce Regulated Necrosis-Like Cell Death on Leishmania (Leishmania) Mexicana</article-title>. <source>Parasitol. Res.</source> <volume>117</volume> (<issue>1</issue>), <fpage>45</fpage>&#x2013;<lpage>58</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00436-017-5635-3</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chac&#xf3;n-Vargas</surname> <given-names>K. F.</given-names>
</name>
<name>
<surname>Nogueda-Torres</surname> <given-names>B.</given-names>
</name>
<name>
<surname>S&#xe1;nchez-Torres</surname> <given-names>L. E.</given-names>
</name>
<name>
<surname>Suarez-Contreras</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Villalobos-Rocha</surname> <given-names>J. C.</given-names>
</name>
<name>
<surname>Torres-Martinez</surname> <given-names>Y.</given-names>
</name>
<etal/>
</person-group>. (<year>2017</year>). <article-title>Trypanocidal Activity of Quinoxaline 1,4 Di-N-Oxide Derivatives as Trypanothione Reductase Inhibitors</article-title>. <source>Molecules (Basel Switzerland)</source> <volume>22</volume> (<issue>2</issue>), <elocation-id>220</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/molecules22020220</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dacks</surname> <given-names>J. B.</given-names>
</name>
<name>
<surname>Davis</surname> <given-names>L. A.</given-names>
</name>
<name>
<surname>Sj&#xf6;gren</surname> <given-names>A. M.</given-names>
</name>
<name>
<surname>Andersson</surname> <given-names>J. O.</given-names>
</name>
<name>
<surname>Roger</surname> <given-names>A. J.</given-names>
</name>
<name>
<surname>Doolittle</surname> <given-names>W. F.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Evidence for Golgi Bodies in Proposed 'Golgi-Lacking' Lineages</article-title>. <source>Proc. Biol. Sci.</source> <volume>270 Suppl 2</volume> (<supplement>Suppl 2</supplement>), <fpage>S168</fpage>&#x2013;<lpage>S171</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1098/rsbl.2003.0058</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diamond</surname> <given-names>L. S.</given-names>
</name>
<name>
<surname>Harlow</surname> <given-names>D. R.</given-names>
</name>
<name>
<surname>Cunnick</surname> <given-names>C. C.</given-names>
</name>
</person-group> (<year>1978</year>). <article-title>A New Medium for the Axenic Cultivation of Entamoeba Histolytica and Other Entamoeba</article-title>. <source>Trans. R. Soc. Trop. Med. Hygiene</source> <volume>72</volume> (<issue>4</issue>), <fpage>431</fpage>&#x2013;<lpage>432</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/0035-9203(78)90144-x</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duque-Monta&#xf1;o</surname> <given-names>B. E.</given-names>
</name>
<name>
<surname>G&#xf3;mez-Caro</surname> <given-names>L. C.</given-names>
</name>
<name>
<surname>Sanchez-Sanchez</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Monge</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Hern&#xe1;ndez-Baltazar</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Rivera</surname> <given-names>G.</given-names>
</name>
<etal/>
</person-group>. (<year>2013</year>). <article-title>Synthesis and <italic>In Vitro</italic> Evaluation of New Ethyl and Methyl Quinoxaline-7-Carboxylate 1,4-Di-N-Oxide Against Entamoeba Histolytica</article-title>. <source>Bioorg. Medicinal Chem.</source> <volume>21</volume> (<issue>15</issue>), <fpage>4550</fpage>&#x2013;<lpage>4558</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bmc.2013.05.036</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franco</surname> <given-names>E.</given-names>
</name>
<name>
<surname>V&#xe1;zquez-Prado</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Meza</surname> <given-names>I.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>Fibronectin-Derived Fragments as Inducers of Adhesion and Chemotaxis of Entamoeba Histolytica Trophozoites</article-title>. <source>J. Infect. Dis.</source> <volume>176</volume> (<issue>6</issue>), <fpage>1597</fpage>&#x2013;<lpage>1602</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1086/514160</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilchrist</surname> <given-names>C. A.</given-names>
</name>
<name>
<surname>Baba</surname> <given-names>D. J.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Crasta</surname> <given-names>O.</given-names>
</name>
<name>
<surname>Evans</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Caler</surname> <given-names>E.</given-names>
</name>
<etal/>
</person-group>. (<year>2008</year>). <article-title>Targets of the Entamoeba Histolytica Transcription Factor URE3-BP</article-title>. <source>PloS Negl. Trop. Dis.</source> <volume>2</volume> (<issue>8</issue>), <fpage>e282</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pntd.0000282</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilchrist</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Mykytka</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Rexach</surname> <given-names>M.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Accelerating the Rate of Disassembly of Karyopherin.Cargo Complexes</article-title>. <source>J. Biol. Chem.</source> <volume>277</volume> (<issue>20</issue>), <fpage>18161</fpage>&#x2013;<lpage>18172</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1074/jbc.M112306200</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>G&#xf3;mez-Caro</surname> <given-names>L. C.</given-names>
</name>
<name>
<surname>S&#xe1;nchez-S&#xe1;nchez</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Bocanegra-Garc&#xed;a</surname> <given-names>V.</given-names>
</name>
<name>
<surname>Rivera</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Monge</surname> <given-names>A.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Synthesis of Quinoxaline 1, 4-Di-N-Oxide Derivatives on Solid Support Using Room Temperature and Microwave-Assisted Solvent-Free Procedures</article-title>. <source>Qu&#xed;mica Nova</source> <volume>34</volume> (<issue>7</issue>), <fpage>1147</fpage>&#x2013;<lpage>1151</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1590/S0100-40422011000700008</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Gonz&#xe1;lez</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Cerecetto</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Monge</surname> <given-names>A.</given-names>
</name>
</person-group> (<year>2007</year>). &#x201c;<article-title>Quinoxaline 1,4-Dioxide and Phenazine 5,10-Dioxide. Chemistry and Biology</article-title>,&#x201d; in <source>Bioactive Heterocycles V. Topics in Heterocyclic Chemistry</source>, vol. <volume>11</volume> . Ed. <person-group person-group-type="editor">
<name>
<surname>Khan</surname> <given-names>M. T. H.</given-names>
</name>
</person-group> (<publisher-loc>Berlin, Heidelberg</publisher-loc>: <publisher-name>Springer</publisher-name>). doi:&#xa0;<pub-id pub-id-type="doi">10.1007/7081_2007_066</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gwairgi</surname> <given-names>M. A.</given-names>
</name>
<name>
<surname>Ghildyal</surname> <given-names>R.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Nuclear Transport in Entamoeba Histolytica: Knowledge Gap and Therapeutic Potential</article-title>. <source>Parasitology</source> <volume>145</volume> (<issue>11</issue>), <fpage>1378</fpage>&#x2013;<lpage>1387</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1017/S0031182018000252</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haraldsen</surname> <given-names>J. D.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Botting</surname> <given-names>C. H.</given-names>
</name>
<name>
<surname>Walton</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Storm</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Phalen</surname> <given-names>T.</given-names>
</name>
<etal/>
</person-group>. (<year>2009</year>). <article-title>Identification of Conoidin A as a Covalent Inhibitor of Peroxiredoxin II</article-title>. <source>Organic Biomol. Chem.</source> <volume>7</volume>, <fpage>3040</fpage>&#x2013;<lpage>3048</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1039/b901735f</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herman</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Siegesmund</surname> <given-names>M. A.</given-names>
</name>
<name>
<surname>Bottery</surname> <given-names>M. J.</given-names>
</name>
<name>
<surname>van Aerle</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Shather</surname> <given-names>M. M.</given-names>
</name>
<name>
<surname>Caler</surname> <given-names>E.</given-names>
</name>
<etal/>
</person-group>. (<year>2017</year>). <article-title>Membrane Trafficking Modulation During Entamoeba Encystation</article-title>. <source>Sci. Rep.</source> <volume>7</volume> (<issue>1</issue>), <fpage>12854</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-017-12875-6</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishikawa</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Sugiyama</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Kurita</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Yokoyama</surname> <given-names>A.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Synthesis and Antimicrobial Activity of 2,3-Bis(Bromomethyl)Quinoxaline Derivatives</article-title>. <source>Bioorg. Chem.</source> <volume>41-42</volume>, <fpage>1</fpage>&#x2013;<lpage>5</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bioorg.2011.12.002</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaplum</surname> <given-names>V.</given-names>
</name>
<name>
<surname>Cogo</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Sangi</surname> <given-names>D. P.</given-names>
</name>
<name>
<surname>Ueda-Nakamura</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Corr&#xea;a</surname> <given-names>A. G.</given-names>
</name>
<name>
<surname>Nakamura</surname> <given-names>C. V.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>
<italic>In Vitro</italic> and <italic>In Vivo</italic> Activities of 2,3-Diarylsubstituted Quinoxaline Derivatives Against Leishmania Amazonensis</article-title>. <source>Antimicrobial Agents Chemother.</source> <volume>60</volume> (<issue>6</issue>), <fpage>3433</fpage>&#x2013;<lpage>3444</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/AAC.02582-15</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kazy</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Puh&#xf3;</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Czeizel</surname> <given-names>A. E.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Teratogenic Potential of Vaginal Metronidazole Treatment During Pregnancy</article-title>. <source>Eur. J. Obstetrics Gynecol. Reprod. Biol.</source> <volume>123</volume> (<issue>2</issue>), <fpage>174</fpage>&#x2013;<lpage>178</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ejogrb.2005.03.016</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kobiler</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Mirelman</surname> <given-names>D.</given-names>
</name>
</person-group> (<year>1981</year>). <article-title>Adhesion of Entamoeba Histolytica Trophozoites to Monolayers of Human Cells</article-title>. <source>J. Infect. Dis.</source> <volume>144</volume> (<issue>6</issue>), <fpage>539</fpage>&#x2013;<lpage>546</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/infdis/144.6.539</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname> <given-names>S. H.</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>S. J.</given-names>
</name>
<name>
<surname>Song</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Gong</surname> <given-names>Y. D.</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>S. Y.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Anti-Cancer Effect of a Quinoxaline Derivative GK13 as a Transglutaminase 2 Inhibitor</article-title>. <source>J. Cancer Res. Clin. Oncol.</source> <volume>139</volume> (<issue>8</issue>), <fpage>1279</fpage>&#x2013;<lpage>1294</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00432-013-1433-1</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leeson</surname> <given-names>P. D.</given-names>
</name>
<name>
<surname>Davis</surname> <given-names>A. M.</given-names>
</name>
<name>
<surname>Steele</surname> <given-names>J.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Drug-Like Properties: Guiding Principles for Design - Or Chemical Prejudice</article-title>? <source>Drug Discovery Today Technol.</source> <volume>1</volume> (<issue>3</issue>), <fpage>189</fpage>&#x2013;<lpage>195</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ddtec.2004.11.005</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Livak</surname> <given-names>K. J.</given-names>
</name>
<name>
<surname>Schmittgen</surname> <given-names>T. D.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2(-Delta Delta C(T)) Method</article-title>. <source>Methods (San Diego Calif.)</source> <volume>25</volume> (<issue>4</issue>), <fpage>402</fpage>&#x2013;<lpage>408</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manich</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Hernandez-Cuevas</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Ospina-Villa</surname> <given-names>J. D.</given-names>
</name>
<name>
<surname>Syan</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Marchat</surname> <given-names>L. A.</given-names>
</name>
<name>
<surname>Olivo-Marin</surname> <given-names>J. C.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>Morphodynamics of the Actin-Rich Cytoskeleton in <italic>Entamoeba Histolytica</italic>
</article-title>. <source>Front. Cell. Infect. Microbiol.</source> <volume>8</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fcimb.2018.00179</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mu</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y.</given-names>
</name>
<etal/>
</person-group>. (<year>2014</year>). <article-title>N-Oxide Reduction of Quinoxaline-1,4-Dioxides Catalyzed by Porcine Aldehyde Oxidase Ssaox1</article-title>. <source>Drug Metab. Disposition: Biol. Fate Chemicals</source> <volume>42</volume> (<issue>4</issue>), <fpage>511</fpage>&#x2013;<lpage>519</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1124/dmd.113.055418</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Novikoff</surname> <given-names>A. B.</given-names>
</name>
<name>
<surname>Novikoff</surname> <given-names>P. M.</given-names>
</name>
<name>
<surname>Davis</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Quintana</surname> <given-names>N.</given-names>
</name>
</person-group> (<year>1972</year>). <article-title>Studies on Microperoxisomes. II. A Cytochemical Method for Light and Electron Microscopy</article-title>. <source>J. Histochem. Cytochem. Off. J. Histochem. Soc.</source> <volume>20</volume> (<issue>12</issue>), <fpage>1006</fpage>&#x2013;<lpage>1023</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/20.12.1006</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Penuliar</surname> <given-names>G. M.</given-names>
</name>
<name>
<surname>Furukawa</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Nakada-Tsukui</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Husain</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Sato</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Nozaki</surname> <given-names>T.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Transcriptional and Functional Analysis of Trifluoromethionine Resistance in Entamoeba Histolytica</article-title>. <source>J. Antimicrobial Chemother.</source> <volume>67</volume> (<issue>2</issue>), <fpage>375</fpage>&#x2013;<lpage>386</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/jac/dkr484</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perdomo</surname> <given-names>D.</given-names>
</name>
<name>
<surname>A&#xef;t-Ammar</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Syan</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Sachse</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Jhingan</surname> <given-names>G. D.</given-names>
</name>
<name>
<surname>Guill&#xe9;n</surname> <given-names>N.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Cellular and Proteomics Analysis of the Endomembrane System From the Unicellular Entamoeba Histolytica</article-title>. <source>J. Proteomics</source> <volume>112</volume>, <fpage>125</fpage>&#x2013;<lpage>140</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jprot.2014.07.034</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perez-Riverol</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Bai</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Bandla</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Garc&#xed;a-Seisdedos</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Hewapathirana</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Kamatchinathan</surname> <given-names>S.</given-names>
</name>
<etal/>
</person-group>. (<year>2022</year>). <article-title>The PRIDE Database Resources in 2022: A Hub for Mass Spectrometry-Based Proteomics Evidences</article-title>. <source>Nucleic Acids Res.</source> <volume>50</volume> (<issue>D1</issue>), <fpage>D543</fpage>&#x2013;<lpage>D552</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/nar/gkab1038</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pineda</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Perdomo</surname> <given-names>D.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Entamoeba Histolytica Under Oxidative Stress: What Countermeasure Mechanisms Are in Place</article-title>? <source>Cells</source> <volume>6</volume> (<issue>4</issue>), <elocation-id>44</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cells6040044</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qiu</surname> <given-names>Q. S.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>V-ATPase, ScNhx1p and Yeast Vacuole Fusion</article-title>. <source>J. Genet. Genomics</source> <volume>39</volume> (<issue>4</issue>), <fpage>167</fpage>&#x2013;<lpage>171</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jgg.2012.02.001</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodrigues</surname> <given-names>J. H.</given-names>
</name>
<name>
<surname>Ueda-Nakamura</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Corr&#xea;a</surname> <given-names>A. G.</given-names>
</name>
<name>
<surname>Sangi</surname> <given-names>D. P.</given-names>
</name>
<name>
<surname>Nakamura</surname> <given-names>C. V.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>A Quinoxaline Derivative as a Potent Chemotherapeutic Agent, Alone or in Combination With Benznidazole, Against Trypanosoma Cruzi</article-title>. <source>PloS One</source> <volume>9</volume> (<issue>1</issue>), <elocation-id>e85706</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0085706</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rustia</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Shubik</surname> <given-names>P.</given-names>
</name>
</person-group> (<year>1972</year>). <article-title>Induction of Lung Tumors and Malignant Lymphomas in Mice by Metronidazole</article-title>. <source>J. Natl. Cancer Institute</source> <volume>48</volume> (<issue>3</issue>), <fpage>721</fpage>&#x2013;<lpage>729</lpage>.</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santiva&#xf1;ez-Veliz</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Moreno-Viguri</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Monge</surname> <given-names>A.</given-names>
</name>
<name>
<surname>P&#xe9;rez-Silanes</surname> <given-names>S.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Quinoxalinas Como Potenciales Agentes Antimycobacterium Tuberculosis: Una Revisi&#xf3;n</article-title>. <source>Rev. la Sociedad Qu&#xed;mica del Per&#xfa;</source> <volume>79</volume> (<issue>3</issue>), <fpage>272</fpage>&#x2013;<lpage>285</lpage>.</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schlosser</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Leitsch</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Duch&#xea;ne</surname> <given-names>M.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Entamoeba Histolytica: Identification of Thioredoxin-Targeted Proteins and Analysis of Serine Acetyltransferase-1 as a Prototype Example</article-title>. <source>Biochem. J.</source> <volume>451</volume> (<issue>2</issue>), <fpage>277</fpage>&#x2013;<lpage>288</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1042/BJ20121798</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serbzhinskiy</surname> <given-names>D. A.</given-names>
</name>
<name>
<surname>Clifton</surname> <given-names>M. C.</given-names>
</name>
<name>
<surname>Sankaran</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Staker</surname> <given-names>B. L.</given-names>
</name>
<name>
<surname>Edwards</surname> <given-names>T. E.</given-names>
</name>
<name>
<surname>Myler</surname> <given-names>P. J.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Structure of an ADP-Ribosylation Factor, ARF1, From Entamoeba Histolytica Bound to Mg(2+)-GDP</article-title>. <source>Acta Crystallographica. Section F Struct. Biol. Commun.</source> <volume>71</volume>(<issue>5</issue>), <fpage>594</fpage>&#x2013;<lpage>599</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1107/S2053230X15004677</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soid-Raggi</surname> <given-names>L. G.</given-names>
</name>
<name>
<surname>Torres-M&#xe1;rquez</surname> <given-names>M. E.</given-names>
</name>
<name>
<surname>Meza</surname> <given-names>I.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Entamoeba Histolytica: Identification of Functional Gs and Gi Proteins as Possible Signal Transduction Elements in the Interaction of Trophozoites With Fibronectin</article-title>. <source>Exp. Parasitol.</source> <volume>90</volume> (<issue>3</issue>), <fpage>262</fpage>&#x2013;<lpage>269</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1006/expr.1998.4333</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soto-S&#xe1;nchez</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Caro-G&#xf3;mez</surname> <given-names>L. A.</given-names>
</name>
<name>
<surname>Paz-Gonz&#xe1;lez</surname> <given-names>A. D.</given-names>
</name>
<name>
<surname>Marchat</surname> <given-names>L. A.</given-names>
</name>
<name>
<surname>Rivera</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Moo-Puc</surname> <given-names>R.</given-names>
</name>
<etal/>
</person-group>. (<year>2020</year>). <article-title>Biological Activity of Esters of Quinoxaline-7-Carboxylate 1,4-Di-N-Oxide Against E. Histolytica and Their Analysis as Potential Thioredoxin Reductase Inhibitors</article-title>. <source>Parasitol. Res.</source> <volume>119</volume> (<issue>2</issue>), <fpage>695</fpage>&#x2013;<lpage>711</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00436-019-06580-8</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tazreiter</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Leitsch</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Hatzenbichler</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Mair-Scorpio</surname> <given-names>G. E.</given-names>
</name>
<name>
<surname>Steinborn</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Schreiber</surname> <given-names>M.</given-names>
</name>
<etal/>
</person-group>. (<year>2008</year>). <article-title>Entamoeba Histolytica: Response of the Parasite to Metronidazole Challenge on the Levels of mRNA and Protein Expression</article-title>. <source>Exp. Parasitol.</source> <volume>120</volume> (<issue>4</issue>), <fpage>403</fpage>&#x2013;<lpage>410</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.exppara.2008.09.011</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teixeira</surname> <given-names>J. E.</given-names>
</name>
<name>
<surname>Huston</surname> <given-names>C. D.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Evidence of a Continuous Endoplasmic Reticulum in the Protozoan Parasite Entamoeba Histolytica</article-title>. <source>Eukaryotic Cell</source> <volume>7</volume> (<issue>7</issue>), <fpage>1222</fpage>&#x2013;<lpage>1226</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/EC.00007-08</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trissl</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Martinez-Palomo</surname> <given-names>A.</given-names>
</name>
<name>
<surname>de Su&#xe1;rez Perez</surname> <given-names>E.</given-names>
</name>
</person-group> (<year>1978</year>). <article-title>Phagocytosis of Human Erythrocytes by Entamoeba Histolytica. Quantitative Study</article-title>. <source>Archivos Investigacion Med.</source> <volume>9</volume>, <fpage>219</fpage>&#x2013;<lpage>222</lpage>.</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Upcroft</surname> <given-names>J. A.</given-names>
</name>
<name>
<surname>Upcroft</surname> <given-names>P.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>Drug Resistance and Giardia</article-title>. <source>Parasitol. Today (Personal ed.)</source> <volume>9</volume> (<issue>5</issue>), <fpage>187</fpage>&#x2013;<lpage>190</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/0169-4758(93)90144-5</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Upcroft</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Upcroft</surname> <given-names>J. A.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Drug Targets and Mechanisms of Resistance in the Anaerobic Protozoa</article-title>. <source>Clin. Microbiol. Rev.</source> <volume>14</volume> (<issue>1</issue>), <fpage>150</fpage>&#x2013;<lpage>164</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/CMR.14.1.150-164.2001</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vicente</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Villar</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Solano</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Berruguete</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Ancizu</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Silanes</surname> <given-names>S. P.</given-names>
</name>
<etal/>
</person-group>. (<year>2007</year>). <article-title>Derivados De 1, 4-Di-N-&#xd3;xido De Quinoxalina Y Enfermedades Olvidadas</article-title>. <source>In Anales la Real Academia Nacional Farmacia</source> <volume>4</volume>, <fpage>927</fpage>&#x2013;<lpage>945</lpage>.</citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Voigt</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Olivo</surname> <given-names>J. C.</given-names>
</name>
<name>
<surname>Sansonetti</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Guill&#xe9;n</surname> <given-names>N.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Myosin IB From Entamoeba Histolytica is Involved in Phagocytosis of Human Erythrocytes</article-title>. <source>J. Cell Sci.</source> <volume>112</volume> (<issue>Pt 8</issue>), <fpage>1191</fpage>&#x2013;<lpage>1201</lpage>. doi: <pub-id pub-id-type="doi">10.1242/jcs.112.8.1191</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="web">
<person-group person-group-type="author">
<collab>WHO</collab>
</person-group> (<year>1998</year>). <source>The World Health Report 1998. Life in the 21st Century A Vision for All</source>. Available at: <uri xlink:href="https://apps.who.int/iris/handle/10665/42065">https://apps.who.int/iris/handle/10665/42065</uri>.</citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Ghai</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Field</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>G. L.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Mammalian Adenylyl Cyclase-Associated Protein 1 (CAP1) Regulates Cofilin Function, the Actin Cytoskeleton, and Cell Adhesion</article-title>. <source>J. Biol. Chem.</source> <volume>288</volume> (<issue>29</issue>), <fpage>20966</fpage>&#x2013;<lpage>20977</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1074/jbc.M113.484535</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>